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ABSTRACT
REGULATION OF THE CYSTINE/GLUTAMATE ANTIPORTER AND ITS
CONTRIBUTION TO NEURONAL DEATH
Rebecca Lee Albano, B.S.
Marquette University, 2016
The aim of this thesis is to better understand the regulation of the
cystine/glutamate antiporter (system xc-) and its role in regulating neuronal survival and
death. Expressed primarily on astrocytes, system xc- takes up cystine and releases
glutamate in a 1:1 ratio. Cystine uptake is the rate-limiting step in glutathione synthesis,
the brain’s main antioxidant. Glutamate released into the extrasynaptic space can
regulate neuronal function; however excessive glutamate release can cause excitotoxicity.
The dual actions of system xc- make it of interest in many neurodegenerative
diseases where oxidative stress and excitotoxicity are involved. We investigated the
regulation of system xc- in SOD1-G93A transgenic mouse model of ALS. We observed
an increase in cystine uptake and glutamate release through system xc- in spinal cord
slices of SOD1-G93A transgenic mice. We did not observe a change in the function of
the main glutamate clearance transporter, excitatory amino acid transporter (EAAT).
This study was the first to show that system xc- activity is dysregulated in an ALS model
and suggests that the excitotoxicity in the SOD1-G93A transgenic mouse may be due to
increased system xc- activity.
Using primary mixed cortical cultures we assessed how different compounds that
deplete intracellular glutathione (GSH), L-buthionine-sulfoximine (BSO) and diethyl
maleate (DEM), affect system xc- function. Both compounds caused significant
decreases in intracellular GSH levels; however, DEM caused an increase in cystine
uptake through system xc-, while unexpectedly BSO caused a decrease in uptake. Also,
DEM caused a decrease in intracellular cysteine, while BSO increased cysteine levels.
The results suggest that negative feedback by intracellular cysteine is a more important
regulator of system xc- than intracellular GSH.
Transforming growth factor-β1 (TGF-β1) is a cytokine involved in regulating
many cellular processes, including neuronal survival and death. We found that TGF-β1
increased cystine uptake through system xc- in astrocyte-enriched glial cultures via the
MAPK/ERK pathway. TGF-β1 increased the export of GSH from astrocytes, which
suggests a neuroprotective role; however, in mixed cortical cultures TGF-β1 enhanced
rotenone-induced neurotoxicity through AMPA receptors. The data suggests that the
increase in system xc- activity by TGF-β1 may have antioxidant defenses, but also
exacerbates excitotoxicity.
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CHAPTER I
INTRODUCTION
General Introduction
The increase in human lifespan over the past several decades has been
accompanied by an increase in the prevalence of neurodegenerative diseases. For
example, in 2015 it was estimated that 5.3 million Americans had Alzheimer’s disease
(AD). Neurodegeneration is characterized by a loss of neuronal structure and function,
including neuronal death. These diseases include Alzheimer’s disease (AD), Parkinson’s
disease (PD), amyotrophic lateral sclerosis (ALS), and many more. Although
neurodegenerative diseases affect many people the cause of most of these diseases is still
unknown. However, they share some common characteristics, including excitotoxicity
and oxidative stress, which provides hope that a therapeutic treatment targeting these
factors may be able to help in many of these diseases simultaneously.
The main focus of this thesis is to better understand the regulation of the
cystine/glutamate antiporter (system xc-) and the role it plays in regulating neuronal
survival and death. Mainly located on astrocytes, system xc- takes up cystine into the
cell, where it is used to synthesize glutathione, the brain’s main antioxidant (Figure 1.1).
In exchange for taking up a molecule of cystine, system xc- releases one molecule of
glutamate. The glutamate released in the extrasynaptic space by system xc- is able to
regulate synaptic function. However, if glutamate levels become too high, they can also
cause neuronal death through excitotoxicity. Therefore, the function of system xc- allows
it to play an important role in both oxidative stress and excitotoxicity and is likely to play
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a role in neurodegenerative diseases.

Figure 1.1 The function of system xc- in astrocytes and the effects it has on
neurons. C-C: cystine; Cys: cysteine; GSH: glutathione; Glu: glutamate; xc-:
system xc-; E: excitatory amino acid transporter; A: AMPA receptor; N: NMDA
receptor; M: metabotropic glutamate receptor; MRP-1: multidrug resistance
protein 1
GLUTAMATE NEUROTRANSMISSION
Glutamate is involved in most aspects of normal brain function. Glutamate is the
primary excitatory neurotransmitter in the central nervous system (CNS); as such it is
involved in brain development, cognition, memory, and learning (Erecińska and Silver,
1990; Meldrum, 2000). It is also important in many aspects of cellular metabolism,
including stimulating glycolysis and protein synthesis (Dingledine et al., 1999) .
Glutamate also has a wide array of indirect actions. It is a precursor to γ-aminobutyric
acid (GABA) (Petroff, 2002), the main inhibitory neurotransmitter in the brain, and it is
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one of the three main components of glutathione (GSH) (Meister and Anderson, 1983),
the main endogenous antioxidant in the CNS.
Glutamate has multiple receptors through which it signals, including ionotropic
and metabotropic receptors (Figure 1.2). Due to its many functions, glutamate levels are
tightly regulated. Multiple transporters are responsible for clearing glutamate from the
synapse in order to maintain proper glutamatergic signaling and prevent the
overactivation of glutamate receptors, which can lead to cell death. Below is a brief
review of some of these key aspects of glutamate neurotransmission.

Figure 1.2 A typical tripartite glutamate synapse. A: AMPA receptor; N:
NMDA receptor; M: metabotropic glutamate receptor receptor; E: excitatory
amino acid transporter; Gln: glycine; Gln: glutamate; Sxc: system xc-
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Glutamate Receptors
There are two classes of glutamate receptors: ionotropic receptors and
metabotropic receptors. Ionotropic receptors open to allow ions to flow in and out of the
cell and are responsible for quick, short lasting responses. Metabotropic receptors, on the
other hand, signal through an intracellular second messenger, which results in slower,
longer lasting responses. Glutamatergic ionotropic receptors include 2-amino-3-(5methyl-3- oxo-1,2- oxazol-4-yl)propanoic acid (AMPA)/kainate receptors and N-methylD-Aspartate (NMDA) receptors. There are eight metabotropic glutamate receptors
(mGluR 1-8) that are divided into three main subgroups. Each type of receptor is briefly
described.
AMPA/Kainate Receptors
AMPA receptors have a low affinity for glutamate (EC50 value: 200-500µM)
(Meldrum, 2000) and are composed of a heterotetramer of four subunits (GluR1-4)
(Meldrum, 2000; Traynelis et al., 2010). All AMPA receptors are permeable to sodium
(Na+) and potassium (K+) and the permeability of the receptor to calcium (Ca2+) is
determined by the GluR2 subunit (Hollmann et al., 1991). Unlike the other subunits,
GluR2 can undergo post-transcriptional editing (Sommer et al., 1990). Edited GluR2
subunits contain a positively charged arginine (R) residue instead of a neutral glutamine
(Q) residue and are impermeable to Ca2+ (Sommer et al., 1991). Most AMPA receptors
contain the edited GluR2 subunit and therefore are only permeable to Na+ and K+;
GluR2-lacking AMPA receptors are very permeable to Ca2+ and activation can result in a
rise in intracellular Ca2+ levels (Isaac et al., 2007; Traynelis et al., 2010).
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AMPA receptors are not voltage dependent and open and close quickly. They
mediate the fast initial part of the excitatory postsynaptic potential (EPSP) and are
responsible for most of the fast excitatory synaptic transmission in the brain (Zhang and
Trussell, 1994; Edmonds et al., 1995). AMPA receptor trafficking into and out of the
postsynaptic membrane plays a key role in determining the strength of the synapse
(Malinow and Malenka, 2002; Shepherd and Huganir, 2007; Anggono and Huganir,
2012).
Kainate receptors are composed of a tetramer of four subunits (GluK1-5). They
are permeable to Na+ and K+ and are located on both postsynaptic and presynaptic
neurons (Chittajallu et al., 1999; Dingledine et al., 1999; Meldrum 2000). The function
of kainate receptors is not as well defined. However, it is known that they act as
modulators of synaptic activity through a variety of mechanisms, including regulating the
release of both glutamate and GABA from presynaptic neurons and regulating the
excitability of postsynaptic neurons (Contractor et al., 2011).
NMDA Receptors
NMDA receptors have a high affinity for glutamate (EC50: 2.5-3µM) (Meldrum,
2000) They are a heterotetramer composed of two GluN1 and two GluN2 (GluN2A-D) or
GluN3 subunits; the distribution of isoforms are regionally and developmentally specific
(Watanabe et al., 1992; Laube et al. 1998; Dingledine et al., 1999). There are two main
ways in which NMDA receptors are distinct from AMPA receptors. First, under
physiological conditions NMDA receptor channels are blocked by magnesium (Mg2+)
(Nowak et al., 1984; Dingledine et al., 1999). In order for the Mg2+ block to be removed,
the cell membrane must first be depolarized by AMPA receptors. Once the Mg2+ block is
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removed, Na+, K+, and Ca2+ can flow through the NMDA receptor. Second, NMDA
receptor activation requires the binding of the co-agonist glycine or D-serine (Wilcox et
al., 1996; Laube et al. 1998). Glutamate/NMDA binds to the GluN2 subunit and
glycine/D-serine binds to the GluN1 subunit. NMDA receptors also have multiple
allosteric modulation sites, which affect the activity of the channel (Dingledine et al.,
1999).
Due to its slower kinetics the NMDA receptor is responsible for producing the
slower, longer lasting part of the EPSP (Vargas-Caballero and Robinson, 2004). NMDA
receptor activation leads to a rise in intracellular Ca2+ concentrations, which can activate
many signaling pathways and is critical for synaptic plasticity, a mechanism of learning
and memory (Malenka and Nicoll, 1993; Benfenati, 2007; Lüscher and Malenka, 2012).
Metabotropic Glutamate Receptors
Metabotropic receptors consist of an extracellular N-terminus that contains a
ligand-binding site, seven transmembrane domains, and an intracellular C-terminus that
couples to a G-protein (Conn and Pin, 1997; Niswender and Conn, 2010). Activating
metabotropic receptors leads to the activation of the G-coupled protein and an
intracellular signaling cascade. There are eight metabotropic glutamate receptors
(mGluRs) subdivided into three functional groups (Conn and Pin, 1997; Niswender and
Conn, 2010; Willard and Koochekpour, 2013). Group I consists of mGluR1 and mGluR5
and are coupled to Gq proteins (Hermans and Challiss, 2001; Ribeiro et al., 2010). Gq
proteins primarily activate phospholipase C (PLC), which cleave phosphatidylinositol
4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacyl-glycerol (DAG). IP3
releases Ca2+ from the endoplasmic reticulum and DAG stimulates protein kinase C
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(PKC). Both Group II (mGluR2 and mGluR3) and Group III (mGluR4-8) metabotropic
glutamate receptors are coupled to Gi proteins (Conn and Pin, 1997; Niswender and
Conn, 2010; Willard and Koochekpour, 2013). Activation of Gi proteins primarily
inhibits adenylyl cyclase (AC), which decreases cyclic adenosine monophosphate
(cAMP).
mGluRs are primarily located perisynaptically and extrasynaptically on both
postsynaptic and presynaptic neurons and modulate synaptic activity (Conn, 2003).
Activation of postsynaptic mGluRs has been shown to modulate the activity of ion
channels and presynaptic mGluRs inhibit the release of neurotransmitters (Conn and Pin,
1997; Conn, 2003; Ribeiro et al., 2010). mGluRs are also located on glia and their
activation can lead to the release of glutamate from astrocytes and regulate the expression
and function of glutamate transporters (D’Antoni et al., 2008). Glutamate binds to each of
the receptors with varying affinity (Meldrum, 2000).
Glutamate Clearance
Clearing glutamate from the synapse is very important for terminating excitatory
transmission and for keeping extracellular concentration of glutamate below excitotoxic
levels (Nicholls and Attwell, 1990; Kanai and Hediger, 1992; Rothstein et al., 1996; Seal
and Amara, 1999; Liang et al., 2008). Excitatory amino acid transporters (EAATs) are
high capacity glutamate transporters and are the primary mechanism responsible for the
uptake of glutamate out of the synapse (Kanai and Hediger, 1992; Seal and Amara, 1999;
Bridges et al., 2012a). Intracellular glutamate concentrations are in the millimolar range,
while extracellular concentrations are kept in the low micromolar range (RonneEngström et al., 1995; Baker et al., 2003). In order to create such a steep glutamate
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concentration gradient, the uptake of one molecule of glutamate is coupled to the uptake
of three molecules of Na+ and one molecule of hydrogen (H+) and the efflux of one
molecule of K+ (Zerangue and Kavanaugh, 1996a). Five EAATs (EAAT 1-5) have been
cloned. EAAT1/GLAST and EAAT2/GLT-1 are located on astrocytes and are
responsible for the majority of glutamate clearance from the synapse (Rothstein et al.,
1994; Seal and Amara, 1999). EAAT3 and EAAT4 are located on neurons and EAAT5
is primarily expressed in the retina (Rothstein et al., 1994; Wersinger et al., 2006).
Glutamate Microdomains
Along with clearing glutamate from the synapse in order to terminate excitatory
signaling, EAATs located on astrocytes can prevent glutamate in one synapse from
diffusing into and activating receptors in neighboring synapses (Rusakov, 2001).
Similarly, EAATs can also prevent glutamate released into the extrasynaptic space by
astrocytes from diffusing into the synaptic zone (Jabaudon et al., 1999). In this way,
EAATs create microdomains of glutamate (Bridges et al., 2012a). In the hippocampal
synapses glutamate levels peak around 1.1mM, but quickly decay (Clements et al., 1992).
Basal glutamate levels in the extrasynaptic space are 1 to 3µM (Baker et al., 2002), which
is high enough to activate some types of extrasynaptic receptors.
Activation of synaptic and extrasynaptic glutamate receptors by these separate
microdomains of glutamate can lead to different functional outcomes. One of the most
well studied examples is the NMDA receptor. Its activation is critical for neuronal
survival, but at the same time activation can also lead to cell death. Evidence suggests
that this ‘NMDA paradox’ is a result of the receptor’s location (Hardingham and Bading,
2010). It is generally accepted that stimulating synaptic NMDA receptors activate
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intracellular pathways that aid in neuroprotection, while stimulation of extrasynaptic
NMDA receptors activate pathways that promote cell death (Hardingham et al., 2002;
Léveillé et al., 2008). When synaptic NMDA receptors are stimulated the influx of
calcium into the cell induces cyclic-AMP response element binding protein (CREB)
(Hardingham et al., 2002), a transcription factor that regulates many cell survival genes
and has a well-documented role in neuronal protection (Bonni et al., 1999; Mayr and
Montminy, 2001). Synaptic NMDA receptor activation also inhibits the apoptotic
cascade and protects against oxidative stress (Hardingham and Bading, 2010; Léveillé et
al., 2010; Papadia et al., 2008). On the other hand, stimulating extrasynaptic NMDA
receptors turn off CREB activity and leads to mitochondrial dysfunction (Hardingham et
al., 2002). Extrasynaptic NMDA receptor activation also inhibits extracellular signalregulated kinase (ERK) (Ivanov et al., 2006; Léveillé et al., 2008), a kinase that has been
shown to play a role in synaptic NMDA receptor neuroprotection (Hetman and
Kharebava, 2006).
Excitotoxicity
While glutamate is necessary for normal brain function, just a brief exposure of
mature cortical neurons to high levels of glutamate can cause morphological changes and
neuronal death occurs within a few hours (Choi et al., 1987). Under normal
physiological conditions extracellular glutamate concentrations are tightly regulated, but
if the regulation is disrupted and extracellular glutamate concentrations rise,
excitotoxicity can occur. Excitotoxicity is the damage and death of neurons, caused by
an over activation of glutamate receptors (Choi et al., 1987). It is a main pathology in
many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS),
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Alzheimer’s disease (AD), multiple sclerosis (MS), and Parkinson’s Disease (PD) (Leigh
and Meldrum, 1996; Doble, 1999; Koutsilieri and Riederer, 2007; Dong et al., 2009). It
is also a key pathology in stroke/ischemia and traumatic brain injury (Choi, 1988; Hayes
et al., 1988; Yi and Hazell, 2006; Szydlowska and Tymianski, 2010).
Excitotoxicity is calcium dependent (Choi, 1985, 1987; Tymianski et al., 1993).
Overactivation of glutamate receptors results in a large influx of calcium into the cell,
which activates multiple enzymes. Activation of these enzymes leads to an increase in
free radicals, protein breakdown, cell membrane degradation, and DNA damage,
culminating in cell death (Freeman and Crapo, 1982; Mark et al., 2001; Berliocchi et al.,
2005). Excitotoxicity can occur as a result of NMDA receptor overactivation. For
example, in vitro NMDA receptor antagonists significantly block cell death induced by
glutamate (Choi et al., 1988; Tymianski et al., 1993). NMDA overactivation is also
involved in many models of disease. Microglia treated with amyloid-beta (Aβ), a
hallmark of AD, have increased glutamate release, which results in enhanced cortical
neuron toxicity. Multiple NMDA receptor antagonists can block this enhanced toxicity
(Qin et al., 2006). In vivo, excitotoxicity caused by Aβ is blocked by the NMDA receptor
antagonist, memantine (MEM) (Miguel-Hidalgo et al., 2002). In clinical trials, MEM has
been shown to delay clinical signs of AD (Hellweg et al., 2012). It has also been shown
to be protective in other models of excitotoxicity, including the 1-methyl-4phenylpyridinium (MPP+) toxicity model of Parkinson’s disease and an in vivo model of
hypoxia-ischemia (Volbracht et al., 2006), suggesting that NMDA receptor
overactivation is involved.
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Excitotoxicity can also occur as a result of overactivation of GluR2-lacking
AMPA receptors. Motor neurons are vulnerable to kainate toxicity because they have a
high number of GluR2-lacking AMPA receptors; and calcium entry through these
receptors is responsible for the toxicity (Carriedo et al., 1996; Van Den Bosch et al.,
2000; Van Damme et al., 2002). In presymptomatic SOD1-G93A mouse, a model of
ALS, an increase in GluR2-lacking AMPA receptors has been observed and AMPA
receptor antagonists have been shown to increase motor neuron survival and prolong the
survival of these mice (Van Damme et al., 2003; Tortarolo et al., 2006). Overactivation
of AMPA receptors may also play a role in MS. In oligodendrocyte cultures, kainate or
increasing extracellular glutamate levels leads to excitotoxicity, which can be blocked by
AMPA receptor antagonists (Yoshioka et al., 1996; Domercq et al., 2005). AMPA
receptor antagonists have been shown to also improve neurological scores in mice treated
with autoimmune encephalitis (EAE), a model of MS (Smith et al., 2000).
NEURON-ASTROCYTE INTERACTION
Astrocytes, the most common type of glial cell in the brain, are highly organized.
They ensheath synapses and have non-overlapping domains (Ventura and Harris, 1999;
Bushong et al., 2002; Nedergaard et al., 2003). Traditionally, astrocytes are thought of as
playing a supportive role to neurons; more recently, however, many studies are emerging
that show astrocytes are a key player in regulating neurotransmission. Below is a brief
review of some important aspects of the neuron-astrocyte interaction.
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Metabolic Coupling and the Glutamate/Glutamine Cycle
Glucose is the main substrate for energy production in the brain and the astrocyteneuron interaction is critical for maintaining energy homeostasis, as well as normal
glutamatergic transmission. After glutamate is released into the synapse it is taken up by
astrocytes through EAATs, along with three molecules of Na+ (Zerangue and Kavanaugh,
1996a). The increase in intracellular Na+ concentration activates the Na+/K+ pump,
which triggers astrocytes to take up glucose from capillaries, which are covered by
astrocytic end feet. The activation of the Na+/K+ pump also triggers glycolysis, which
metabolizes glucose into lactate, a process that yields two molecules of adenosine
triphosphate (ATP) (Pellerin and Magistretti, 1994; Magistretti and Pellerin, 1999). The
lactate is then released by astrocytes and taken up by neurons, where it is converted into
pyruvate and goes through the tricarboxylic acid (TCA) cycle to supply the neuron with
energy (Tsacopoulos and Magistretti, 1996; Magistretti and Pellerin, 1999). The two
molecules of ATP produced by glycolysis are used to convert glutamate to glutamine by
the enzyme glutamine synthase. Glutamine is then released and taken up by neurons,
where it is converted back into glutamate (Sibson et al., 1998). This metabolic
interaction is illustrated in Figure 1.3. Since this cycle depends on uptake of glutamate
from the synapse following neurotransmission, EAAT activation is an activity-dependent
signaling mechanism for the utilization of glucose (Sibson et al., 1998; Magistretti and
Pellerin, 1999).
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Figure 1.3 Interaction between astrocytes and neurons: metabolic coupling
and the glutamate/glutamine cycle. A: AMPA receptor; N: NMDA receptor;
M: metabotropic glutamate receptor receptor; E: excitatory amino acid transporter
Adapted and modified from (Magistretti and Pellerin, 1999)
Neuronal Regulation of Astrocytes
Like neurons, astrocytes express a wide variety of ion channels and
neurotransmitter receptors, including K+ channels, ionotropic glutamate receptors,
mGluRs, GABA receptors, muscarinic aceylcholine (mAch) receptors and
endocannabinoid (CB) receptors (Barres, 1991; Newman, 2003; Navarrete and Araque,
2008). Neuronal activity can activate these receptors and lead to a wide range of effects.
For example, astrocyte membranes can be depolarized in response to glutamate or in
response to high concentrations of extracellular K+ that result from high neuronal activity
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(Bowman and Kimelberg, 1984; Sontheimer et al., 1988; Usowicz et al., 1989; Murphy et
al., 1993; Meeks and Mennerick, 2007). GABA released from neurons has been shown
to regulate astrocyte morphology through GABAA receptors (Matsutani and Yamamoto,
1997) . Although the mechanism is unknown, neurons can also regulate expression of
glutamate transporter subtypes (Swanson et al., 1997). Activation of many of the Gprotein coupled receptors on astrocytes leads to increased intracellular concentrations of
Ca2+ (Porter and McCarthy, 1996; Araque et al., 2002; Newman, 2003; Navarrete and
Araque, 2008).
Astrocyte Regulation of Neurons
Astrocytes are involved in most aspects of synaptic transmission (Araque et al.,
1999; Newman, 2003; Bridges et al., 2012a). They take part in synaptogenesis by
influencing synapse formation, axonal pruning, and synapse elimination through secreted
and cell-surface signals (Ullian et al., 2001; Eroglu and Barres, 2010). Intracellular Ca2+
waves can cause astrocytes to release vesicular gliotransmitters that regulate neuronal
function and synaptic plasticity (Araque et al., 1999, 2000; Newman, 2003). For
example, glutamate release from astrocytes can increase neuronal Ca2+ levels (Parpura et
al., 1994). Astrocytes influence synaptic plasticity by enhancing neuronal NMDA
receptor activation and enabling induction of long-term potentiation (LTP) through
release of D-serine (Yang et al., 2003) . Non-vesicular release of glutamate from
astrocytes through the cystine/glutamate antiporter (system xc-) can also influence
neuronal transmission through activation of extrasynaptic glutamate receptors (Bridges et
al., 2012a; 2012b; Massie et al., 2015).
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Due to its highly branched morphology, one astrocyte is able to interact with tens
of thousands of synapses (Halassa et al., 2007), which allows them to synchronize
neuronal activity (Rouach et al., 2008). It also allows for neurons to influence synaptic
transmission of neighboring synapses by signaling through astrocytes (Araque et al.,
1999; Angulo et al., 2004; Navarrette and Araque, 2008). And although astrocytes have
non-overlapping domains, they are coupled together by gap junctions (Dermietzel et al.,
1991; Giaume et al., 1991), through which signals spread rapidly between astrocytes,
allowing them to work together as a network (Rouach et al., 2008; Giaume et al., 2010).
OXIDATIVE STRESS
A common pathology in many neurodegenerative diseases discussed in this thesis
is oxidative stress. Oxidative stress is an accumulation of reactive oxygen species (ROS)
due to an imbalance between the production of ROS and the body’s ability to eliminate
them. Common ROS include superoxide (O2-), hydroxyl radical (OH-) and hydrogen
peroxide (H2O2). The brain is particularly vulnerable to oxidative stress because of its
high oxygen consumption.
Production and Elimination of ROS
There are two main sources of intracellular ROS production. First, ROS are
produced during normal mitochondrial oxidative metabolism. During cellular respiration
electrons from the mitochondria leak out and react with oxygen, forming O2-, the
precursor of most other ROS (Freeman and Crapo, 1982; Kirkinezos and Moraes, 2001;
Turrens, 2003) . The second source is from activity of the membrane bound enzyme
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. NADPH oxidases are
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found in neurons, astrocytes, and microglia; and when active they generate O2- as
electrons cross the cell membrane and couple with oxygen (Infanger et al., 2006; Sorce
and Krause, 2009) .
As seen in Figure 1.4 cells have various defense mechanisms against ROS,
including superoxide dismutases (SOD), catalase, and glutathione (GSH). SODs are a
class of enzymes that catalyze O2- into H2O2 (Fridovich, 1975). While H2O2 itself is not
reactive, the bond between the two oxygen atoms is very weak and it can form the highly
reactive hydroxyl radical OH- via the Fenton reaction (Winterbourn, 1995). Some H2O2
reacts with a catalase to form the non-harmful byproducts, water and oxygen (George,
1947). The majority of H2O2 is removed by GSH in a reaction catalyzed by glutathione
peroxidase, which oxidizes GSH into glutathione disulfide (GSSG) and forms water
(Finley et al., 1981; Winterbourn and Metodiewa, 1994). GSSG can be converted back
into GSH by glutathione reductase and the reduced form of NADPH (Simonian and
Coyle, 1996). Under normal conditions, 99% of total cellular GSH is in the reduced
form. However, when oxidative stress occurs, GSSG is rapidly produced and
accumulates in the cell (Deneke and Fanburg, 1989).
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Figure 1.4 Cellular pathways involved in regulating O2. GSH: glutathione;
GSSG: oxidized glutathione; H2O: water; O2: oxygen: O2-: superoxide; OH-:
hydroxal radical; H2O2: hydrogen peroxide; Fe: iron
Oxidative stress occurs when there is an accumulation of ROS, due to an
imbalance between ROS production and removal, which can occur through a number of
mechanisms. For example, middle cerebral artery occlusion in mice upregulates NADPH
oxidase expression in the mouse brain resulting in an increase in ROS production (Vallet
et al., 2005) . Mitochondrial dysfunction is a common mechanism behind increased ROS
production; multiple new therapeutics are aimed at targeting the mitochondria because
mitochondrial dysfunction is a main pathology in many neurodegenerative diseases (Lin
and Beal, 2006; Federico et al., 2012; Lee, 2016). Decreased ROS removal can also
make cells more susceptible to oxidative damage. For example, dopaminergic neurons
co-cultured with astrocytes show increased toxicity to H202 when the astrocytes have
been depleted of GSH (Drukarch et al., 1997). Increased intracellular ROS causes
damage to DNA, protein oxidation, and damage to the plasma membrane via lipid
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peroxidation (Freeman and Crapo, 1982; Berliocchi et al., 2005). Prolonged exposure to
oxidative stress leads to cell death.
Glutathione Metabolism
GSH, a tripeptide composed of cysteine, glutamate, and glycine, is the major
antioxidant found in the brain. GSH synthesis occurs intraceullularly in a two-step
process (Meister and Anderson, 1983). First, the enzyme glutamate-cysteine ligase
(GCL) catalyzes glutamate and cysteine to produce the dipeptide, γ-glutamylcysteine
(γGluCys). Glycine is then added to the dipeptide by GSH synthase (GS) to form GSH.
Both steps require ATP and GSH metabolism is dependent upon the availability of
glutamate, cysteine, and glycine. Since glutamate and glycine are highly available, the
uptake of cystine or cysteine into the cell is the rate-limiting step in GSH synthesis
(Sagara et al., 1993a; Dringen and Hirrlinger, 2003).
There are two well characterized mechanisms found on astrocytes and neurons
that take up cystine or cysteine: system xc- and the glutamate/aspartate/cysteine
transporter (EAAC1/EAAT3). Astrocytes transport cystine, mainly through system xc(Sagara et al., 1993a; Kranich et al., 1998; Bridges et al., 2012b). Once inside the cell,
cystine is rapidly reduced into two cysteine molecules and metabolized into GSH
(Dringen and Hirrlinger, 2003). Neurons, on the other hand, have limited ability to take
up cystine as a GSH precursor. Instead neurons rely on cysteine or cysteinylglycine
(CysGly) provided by astrocytes (Sagara et al., 1993a; Dringen et al., 1999; Wang and
Cynader, 2000; Dringen and Hirrlinger, 2003). Astrocytes export GSH into the
extracellular space through multidrug resistance protein-1 (Mrp-1) (Minich et al., 2006),
where it can be broken down by γ-glutamyl-transpeptidase into glutamate and CysGly
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(Hanigan and Rickets, 1993). Aminopeptidase-N, expressed on the cell membrane of
neurons, then breaks CysGly down into glycine and cysteine (Dringen et al., 2001).
Neurons then take up the extracellular cysteine through EAAT3 to synthesize GSH
(Sagara et al., 1993a; Zerangue and Kavanaugh, 1996b; McBean, 2002). Without the
GSH/cysteine supplied by astrocytes, neurons are much more susceptible to oxidative
insults (Drukarch et al., 1997; Abramov et al., 2003; Shih et al., 2003). GSH metabolism
is illustrated in Figure 1.5.
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Figure 1.5 Interaction between astrocytes and neurons: GSH metabolism.
Cystine (C-C) enters astrocytes through system xc- and is rapidly reduced to
cysteine (cys). Glutamate-cysteine ligase (GCL) catalyzes glutamate and cysteine
to γ-glutamylcysteine (Cys-Glu). Glycine (Gly) is added to the dipeptide by GSH
synthase (GS) to form the tripeptide glutathione (GSH). Astrocytes then export
GSH through multidrug resistance protein 1 (MRP-1) into the extracellular space
where it is broken down into cysteinylglycine (Cys-Gly) by γglutamyltransferase
(γGT). It is further broken down into glycine and cysteine by aminopeptidase
(AP-N). Cysteine can then be taken up into neurons via EAAT3 (E), where it is
metabolized into GSH. Adapted and modified from (Bridges et al., 2012)
Although GSH is the main antioxidant in the brain, compared to other tissues the
concentration of GSH is low. The concentration also varies between cells types; for
example, the concentration in neurons is ~2.5mM and in astrocytes it is ~3.8mM (Rice
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and Russo-Menna, 1998) . The brain’s high oxygen consumption and low concentration
of GSH makes it, particularly the neurons, susceptible to oxidative stress.
TRANSFORMING GROWTH FACTOR-β1
Transforming growth factor-β1 (TGF-β1), first discovered in the early 1980s, is a
cytokine with wide ranging effects both in development and in the adult brain, including
regulating cellular processes like growth and development (Böttner et al., 2000;
Massagué et al., 2000), differentiation (Ishihara et al., 1994), and apoptosis (Prehn et al.,
1994; Zhu et al., 2001; 2002). TGF-β1 is one of three TGF-β isoforms and is part the
TGF-β superfamily, which includes multiple cytokines. Its expression is very low during
development and in the adult brain (Flanders et al., 1991; Pelton et al., 1991; Unsicker et
al., 1991). While some studies show it is mainly confined to the meninges and choroid
plexus (Unsicker et al., 1991), others have found it is present in the cerebral cortex
(Vivien et al., 1998).
Receptors and Intracellular Signaling
When TGF-β1 is first synthesized it becomes part of a large latent complex (LLC)
contained in the cell’s extracellular matrix (Akhurst and Hata, 2012). The complex is
composed of a TGF-β1 homodimer, a latency-associated peptide (LAP), and a latent
TGFβ binding protein (LTBP). When TGF-β1 is activated the LLC is released from the
extracellular matrix and the LAP and LTBP are broken down, releasing TGF-β1. Upon
its release TGF-β1 is able to interact with its receptors: TGF-β receptor I and II (TGFβRI, -II) (Massagué, 1998). Both TGF-βRI and TGF-βRII are serine/threonine kinases
and are expressed on neurons, astrocytes, and microglia throughout the brain (Böttner et
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al., 1996; Vivien et al., 1998; Vivien and Ali, 2006). There are two TGF-βRI isoforms
that TGF-β1 signals through: activin receptor-like kinase 1 (ALK1) and ALK5
(Massagué, 1998; Akhurst and Hata, 2012). Signaling begins when TGF-β1 binds to
TGF-βRII, which recruits and phosphorylates TGF-βRI. Following activation, TGF-βRI
phosphorylates and activates receptor specific signaling mother against decapentaplegic
(R-SMAD) proteins, which then associate with its common mediator SMAD (C-SMAD).
Together R-SMAD and C-SMAD translocate to the nucleus where they regulate gene
transcription (Figure 1.6).

Figure 1.6 The canonical TGF-β1 signaling pathway. Adapted and modified
from (Massagué, 2000)
Recently other signaling pathways of TGF-βRI/II activation have begun to
emerge (Figure 1.7) (Massagué, 2000; Vivien and Ali, 2006; Akkhurt and Hata, 2012).
Through crosstalk these non-canonical pathways and the SMAD pathways can modulate
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each other. Also, along with being serine/threonine kinases, recently it was discovered
that TGF-βRI/II can also phosphorylate tyrosine, which plays a role in activating the
mitogen-activated protein kinase/ extracellular signal-regulated kinase (MAPK/ERK)
signaling pathway (Lee et al., 2007; Zhang, 2009).

Figure 1.7 The non-canonical TGF-β1 signaling pathway. Adapted and
modified from (Akhurt and Hata, 2012)
TGF-β1 in Brain Disorders
While TGF-β1 expression is very low in the adult brain (Flanders et al., 1991;
Pelton et al., 1991; Unsicker et al., 1991) in response to injury and neurodegeneration
TGF-β1 is highly upregulated and secreted by many different cell types (Pratt and
McPherson, 1997; Flanders et al., 1998; Vivien and Ali, 2006), suggesting it plays a role
in regulating neuronal survival and death. In fact TGF-β1 knockout mice have
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widespread neuronal degeneration (Brionne et al., 2003), which reveals a role for TGF-β1
in regulating neuronal survival. Below is a brief description of some of the diseases TGFβ1 has been shown to be upregulated in and the role it plays in neuronal survival/death.
Amyotrophic Lateral Sclerosis
TGF-β1 is increased in both the SOD1-G93A mouse model of amyotrophic lateral
sclerosis (ALS) and in the cerebral spinal fluid (CSF), plasma, and ventral horn of ALS
patients; levels of TGF-β1 are positively correlated with the duration of the disease (Houi
et al., 2002; Iłzecka et al., 2002; Endo et al., 2015). In SOD1-G93A mutant mice,
overproduction of TGF-β1 in astrocytes resulted in a decreased inflammatory reaction by
microglia, which accelerated disease progression in a non-cell autonomous manner (Endo
et al., 2015). This suggests that TGF-β1 negatively regulates disease progression. In
further support of this, inhibiting TGF-β1 signaling led to a decrease in disease
progression and extended the survival time in SOD1-G93A mice (Endo et al., 2015).
Alzheimer’s Disease
While increased levels of TGF-β1 have been observed in in the CSF, serum, and
even in the amyloid-β (Aβ) plaques of patients with Alzheimer’s disease (AD) (van der
Wal et al., 1993; Chao et al., 1994; Zetterberg et al., 2004), the effects of this increase are
unknown. In fact, there is conflicting data as to whether increased TGF-β1 plays a role in
driving disease pathology or is neuroprotective. Overexpression of TGF-β1 in mice has
been shown to lead to overexpression of amyloid precursor protein (APP), which drives
Aβ production in astrocytes (Lesné et al., 2003) and increases Aβ deposition in cerebral
blood vessels and meninges (Wyss-Coray et al., 1997). These studies suggest that TGF-
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β1 may enhance AD pathology. However, TGF-β1 has also been shown to be protective
against Aβ toxicity in hippocampal cultures (Ren and Flanders, 1996) and in Aβ-induced
AD mouse models (Shen et al. 2014; Chen et al., 2015). Beneficial effects of TGF-β1 in
these models included decreases in production of pro-inflammatory cytokines (Chen et
al., 2015), cognitive deficits, glial activation, APP expression, and neuronal loss (Shen et
al., 2014). Other protective effects of TGF-β1 on Aβ toxicity include preserving
mitochondrial potential (Prehn et al., 1996), inhibiting apoptosis by regulating gene
expression to favor the anti-apoptotic pathway (Kim et al., 1998), and even increasing the
clearance of Aβ (Wyss-Coray et al., 2001).
Ischemia
TGF-β1 has been well studied in models of ischemia. It is upregulated in the
infarct and the area surrounding the vessel occlusion (penumbra) in the brains of stroke
patients (Krupinski et al., 1996). Similarly, following models of focal ischemia in rats
TGF-β1 is also upregulated (Lehrmann et al., 1998; Ruocco et al., 1999) and exerts
neuroprotective effects. For example, injection of TGF-β1 into the ventricles before the
induction of ischemia decreased brain lesion size (Prehn et al., 1993; Henrich-Noack et
al., 1996). TGF-β1 overexpression decreased chemokine expression and infarct size
following middle cerebral artery occlusion (MCAO) and reperfusion (Pang et al., 2001),
while blocking endogenously released TGF-β1 following MCAO increased infarct size
(Ruocco et al., 1999).
Two of the key mechanisms involved in cell death following ischemia are
excitotoxicity and apoptosis. The effects TGF-β1 exerts on insults that induce
excitoxicity or apoptosis have been studied in vitro, in order to better understand the
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mechanism behind its effects on neuronal death. TGF-β1 exerts opposite effects on
slowly-triggered vs rapidly-triggered excitotoxicity. TGF-β1 is protective against short
applications of high doses of glutamate or NMDA (rapidly-triggered excitotoxicity) in
hippocampal and cortical neurons (Prehn and Krieglstein, 1994; Prehn and Miller, 1996;
Bruno et al., 1998). However, TGF-β1 exacerbates the toxicity of long applications of
low doses of glutamate (slowly-triggered excitotoxicity) (Prehn and Miller, 1996). TGFβ1’s protection against NMDA receptor mediated toxicity involves upregulation of type 1
plasminogen activator inhibitor (PAI-1) (Buisson et al., 1998; Docagne et al., 1999). The
protection by PAI-1 is due to its inhibition of tPA, a protein that increases NMDA
toxicity by cleaving the NR1 subunit leading to increased NMDA induced calcium influx
(Nicole et al., 2001). The mechanism behind exacerbation of slowly-triggered
excitotoxicity is unknown.
TGF-β1 protects against apoptosis by regulating the expression of apoptotic
genes. For example, TGF-β1 pretreatment increased expression of the anti-apoptotic
gene, B-cell lymphoma 2 (Bcl2) and Bcl-xl, in hippocampal neurons deprived of trophic
factors (Prehn et al., 1994). TGF-β1 is also able to inhibit the pro-apoptotic gene
caspase-3 and protect hippocampal neurons from staurosporine-induced apoptosis (Zhu et
al., 2001). In vivo, TGF-β1 is able to reduce ischemic lesions and neurological deficits
by inhibiting the pro-apoptotic genes Bad and caspase-3 induced by MCAO; TGF-β1’s
effects are through activation of the MAPK/ERK pathway (Zhu et al., 2002).
SYSTEM XCThe cystine/glutamate antiporter (system xc-) is a sodium-independent, chloridedependent amino acid transporter system localized in the plasma membrane. First

27
characterized in human fibroblast cell cultures, system xc-, is an antiporter that mediates
the uptake of cystine into cells in exchange for exporting glutamate from the cell in a 1:1
ratio (Bannai and Kitamura, 1980; Bannai, 1986).
Structure of System xcSystem xc- is a member of the solute carrier (SLC) 7 family of amino acid
transporters and is a heterodimer composed of two subunits: a 502 amino acid short chain
protein xCT and 4F2hc, the heavy chain subunit. 4F2hc is found in multiple members of
the SLC7 family of transporters and is responsible for the transport of the antiporter to
the plasma membrane (Estévez et al., 1998; Sato et al., 1999; Bassi et al., 2001; Verrey et
al., 2004). The 4F2hc subunit is linked by a disulfide bridge to the xCT subunit (Torrents
et al., 1998; Shih et al., 2006). xCT is encoded by the SLC7a11 gene (Bassi et al., 2001)
and is the functional subunit that confers substrate specificity of the transporter (Sato et
al., 1999; Bassi et a., 2001). It is composed of 12 transmembrane domains and both the
N- and C-terminus are located in the cytoplasm (Gasol et al., 2004) (Figure 1.8).
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Figure 1.8 The structure of system xc-. Adapted and modified from (Shih et al.,
2006)
Function of System xcSystem xc- has three main functions. Due to its dual action of importing one
molecule of cystine in exchange for exporting one molecule of glutamate, it is able to
1) regulate intracellular GSH levels and 2) regulate extracellular glutamate
concentrations. Often overlooked because of its first two functions, system xc- also 3)
plays a role in regulating the redox environment of the cell. Each of these functions is
described in more detail below.
Regulation of GSH Levels
As previously described, GSH is essential for the reduction of ROS in the brain
and protection from oxidative stress; system xc- not only provides astrocytes with the
substrate to synthesize GSH, but it is also critical for GSH synthesis in neurons. Certain
cells rely heavily on system xc- to protect them from oxidative glutamate toxicity.
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Oxidative glutamate toxicity occurs when high levels of extracellular glutamate are
applied to cells that lack glutamate receptors; instead of causing excitotoxicity, high
levels of glutamate competitively inhibit the uptake of cystine through system xc-,
causing GSH depletion, resulting in oxidative stress and cell death (Miyamoto et al.
1989; Murphy et al. 1989; 1990; Sagara et al. 1993b; Ratan et al. 1994). Overexpression
of xCT on astrocytes can protect immature cortical neurons from oxidative glutamate
toxicity (Shih et al., 2006).
System xc- activity is also needed in order to maintain the high levels of GSH
necessary for glioma cells to grow (Chung et al. 2005; Chung and Sontheimer 2009); that
is why when cellular GSH levels are depleted by diethyl maleate (DEM) treatment,
glioma cells increase xCT expression and system xc- activity (Kim et al. 2001).
Upregulation of system xc- can also protect cells from different types of oxidative stress.
For example, insulin-like growth factor 1 (IGF-1) and TGF-β upregulate system xcactivity and protect dental pulp cells against oxidative stress induced by dental materials
(Pauly et al., 2011). Interleukin-1β (IL-1β) upregulates system xc- activity, which
protects astrocytes from ROS-inducing FeSO4 and tert-butyl hydroperoxide (tBOOH)
exposure (He et al., 2015). On the other hand, astrocytes derived from mice with the
subtle gray pigmentation mutant phenotype (sut/sut), an xCT loss of function mutation,
have reduced proliferation as a result of decreased GSH and increased oxidative stress
(Shih et al., 2006). Together these studies show that upregulating system xc- confers
protection against oxidative stress in the cells in which it is upregulated by increasing
cystine uptake, which leads to the production of the antioxidant GSH.
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Extracellular Glutamate Regulation
The second main function of system xc- is the regulation of extracellular
glutamate concentrations. Non-vesicular release of glutamate through system xc- is the
major source of extracellular glutamate in several rodent brain regions (De Bundel et al.,
2011; Massie et al., 2011; Baker et al. 2002) and it is able to regulate neuronal activity
through extrasynaptic glutamate receptors. For example, glutamate released by system
xc- can activate presynaptic mGluR2/3 receptors and inhibit synaptic glutamate release
(Baker et al., 2002; Moran et al., 2005). It can also change receptor levels in the synapse,
which can affect synaptic strength (Augustin et al., 2007; Williams and Featherstone,
2014). Sut/sut mice have impaired long-term potentiation (LTP) and deficits in their
long-term memory (Li et al., 2012) and xCT-/- mice have decreased extracellular
glutamate and impaired spatial working memory (De Bundel et al., 2011).
In contrast to the possible neural protective mechanism of system xc- against
oxidative stress, it has been shown that glutamate release via system xc- can cause
excitotoxicity and lead to neuronal death. The strongest evidence comes from studies
involving glial cells. Activation of microglia can increase glutamate release through
system xc- causing toxicity to cerebellar granule cells (Piani and Fontana, 1994), cortical
neurons (Qin et al., 2006), and oligodendrocytes (Domercq et al. 2007). System xc- on
astrocytes has also been shown to play a role in neuronal death. Activation of astrocytes
with IL-1β leads to increased system xc- mediated glutamate release causing enhanced
excitotoxicity of cortical neurons exposed to hypoxia or glucose deprivation (Fogal et al.,
2007; Jackman et al., 2010). And long-term exposure to fibroblast growth factor-2 (FGF2) upregulates system xc- activity and causes AMPA receptor mediated excitotoxicity in
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cortical neurons (Liu et al., 2012; 2014). Together these studies show that system xc- can
increase extracellular glutamate levels, which can lead to excitotoxicity.
Regulation of the Redox Environment
Finally, system xc- is involved in regulating the redox environment around the cell
membrane by maintaining proper levels of GSH and cystine/cysteine (Conrad and Sato,
2012; Lewerenz et al., 2013). GSH is exported from the cell by MRP-1 and contributes
to the reduced extracellular environment (Wang and Cynader 2000; Dringen and
Hirrlinger 2003). Likewise cysteine can also be directly exported from the cell via
system ASC and oxidized to cystine. System xc- drives this cystine/cysteine cycle, which
helps maintain the redox environment independent of the GSH (Bannai and Ishii 1982;
Anderson et al. 2007). The redox state of the cell is important because it can play a large
role on cell signaling. For example, the NMDA receptor has an extracellular redox site
and changes in the redox environment can affect the open-channel frequency and
potentiate or decrease the magnitude of the response (Aizenman et al., 1989; Tang and
Aizenman, 1993). The redox state can also impact enzyme and transcription factor
activity (Janssen-Heininger et al., 2008).
xCT knockout mice (xCT-/-) provide evidence for the involvement of system xcin redox balance. Sato et al. (2005) found that the plasma in xCT-/- mice is more
oxidized, as a result of higher levels of cystine and lower levels of GSH. Also,
fibroblasts cultured from these mice died unless the reducing agent 2-mercaptoethanol
was added. If 2-mercaptoethanol was removed cysteine and GSH levels decreased and
cells began to die within 24 hours.

32
Regulation of System xcSystem xc- has similar affinities for transport of both cystine and glutamate;
therefore, the concentration gradient of these substrates determines the direction of
transport (Lewerenz et al., 2013). Physiologically, cystine is found at very low
concentrations inside the cell, while glutamate has high intracellular and low extracellular
concentrations thus, intracellular concentrations of glutamate drive the release of
glutamate from the cell through system xc-, which leads to the import of cystine
(Lewerenz et al., 2013). EAATs regulate intracellular/extracellular glutamate
concentrations and, therefore, regulate system xc- activity (Rimaniol et al., 2001;
Lewerenz et al., 2006). Since system xc- can transport glutamate both directions,
increases in extracellular glutamate can act as a competitive inhibitor of cystine uptake
(Bannai, 1986).
Regulation of xCT subunit expression is more important in determining system
xc- activity than the 4F2hc subunit (Lewerenz et al., 2013). The factors that regulate xCT
and mechanisms behind its regulation are still largely unknown. Given its role in
oxidative stress and excitotoxicity, along with its emerging role in many
neurodegenerative diseases, understanding what regulates system xc- is important and
may one day help in developing therapeutic agents for some of these diseases. Below is a
brief description of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant
responsive element (ARE) and the eukaryotic initiation factor-2 (eIF2α)-activating
transcription factor (ATF) 4- amino acid response element (AARE) pathways, which
regulate system xc- expression (Figure 1.9).

33

Figure 1.9 Factors and pathways that regulate the transcription of xCT.
Adapted and modified from (Lewerenz et al., 2012)
Nrf2-ARE Pathway
Oxidative stress is one of the main regulators of system xc-. Xanthine/xanthine
oxidase induced oxidative stress in Müller glial cells causes an upregulation of system xcactivity (Mysona et al., 2009). Also, oxidative stress and nitric oxide upregulate system
xc- activity in a retinal ganglion cell line (RGC-5) (Dun et al., 2006), while oxidative
stress induced by exposure to DEM increases system xc- function in human glioma cells
(Kim et al., 2001).
In response to oxidative and electrophilic stress cells activate the Nrf2-ARE
pathway, which increases the cell’s antioxidant defenses (Itoh et al., 1997), including
intracellular and extracellular GSH levels (Sasaki et al., 2002; Shih et al, 2006). Under
normal conditions, Nrf2 is bound to kelch-like ECH-associated protein 1 (Keap1), which
retains Nrf2 in the cytoplasm. However, in response to ROS and electrophiles Nrf2
dissociates from Keap1 and translocates to the nucleus where it binds to ARE sequences,
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also known as electrophile response elements (EpRE), and activates gene transcription
(Itoh et al., 2004; Taguchi et al., 2011; Kansanen et al., 2013). The Nrf2-ARE pathway is
responsible for activating multiple genes involved in neuronal survival. Many of the
genes activated are involved in the metabolism of GSH, including glutamate-cysteine
ligase, glutathione synthetase, glutathione S-transferase, glutathione reductase, and
multidrug resistance protein 1 (Sasaki et al., 2002; Lee and Johnson, 2004; Shih et al.,
2006). Transcription of xCT, which contains four ARE sequences in the 5’ end of its
gene, is also activated (Sasaki et al., 2002).
Studies show that the Nrf2-ARE pathway can upregulate system xc- in response to
a wide variety of stress agents, including diethyl maleate, H2O2, cadmium, and oxidative
glutamate toxicity in different types of cells (Ishii et al., 2000; Sasaki et al., 2002;
Lewerenz et al., 2009). It is important to note that the Nrf-2-ARE pathway is
preferentially activated in astrocytes (Shih et al., 2006; Johnson et al., 2008) and
upregulation of system xc- through this pathway not only protects astrocytes from
oxidative stress, but also protects neighboring neurons (Shih et al. 2003).
eIF2α-ATF4-AARE Pathway
Amino acid deprivation causes an increase in system xc- activity through
activation of the ATF4-AARE pathway (Sato et al., 2004). Low levels of amino acids
activate the general control non-derepressible-2 (GCN2) protein kinase, which
phosphorylates eIF2α (Zhang et al., 2002; Wek et al., 2006). Composed of eIF2α, eIF2β,
and eIF2γ, eIF2 is part of the initiating complex for most protein synthesis.
Phosphorylation of eIF2α leads to global inhibition of protein synthesis in order to slow
down cellular activity and protect the cell (Wek et al., 2006; Kilberg et al., 2009). While
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translation of most proteins is inhibited, eIF2α phosphorylation induces translation of
select transcripts, like ATF4 (Vattem and Wek, 2004; Wek et al., 2006; Kilberg et al.,
2009). ATF4 binds to the AARE sequence and results in translation of the gene (Kilberg
et al., 2009). The 5’ end of xCT contains two AARE sequences, thus ATF4 binding
results in increased xCT transcription (Sato et al., 2004).
The ATF4-AARE pathway can also be activated by phosphatidylinositide 3kinase (PI3K) in glioblastomas (Lewerenz et al., 2014). High frequency neuronal
activation in vitro activates PI3K, which generates 3,4,5-triphosphate (PIP3) through
phosphorylation of inositol lipids in the membrane (Lewerenz et al., 2014). PIP3
activation leads to Akt activation, which phosphorylates and inhibits glycogen synthase
kinase 3β (GSK-3β) (Hers et al., 2011; Matsuda et al., 2013; Lewerenz et al., 2014). In
turn, inhibition of GSK-3β leads to GCN2 activation and the eIF2α-ATF4-AARE
pathway continues as previously described (Lewerenz et al., 2014).
In embryonic fibroblasts, mutation of the eIF2α phosphorylation site results in
decreased ATF4 expression and system xc- activity (Lewerenz and Maher, 2009).
Likewise, increasing eIF2α phosphorylation in hippocampal HT22 cells increases ATF4
expression and system xc- activity. The increase in system xc- activity led to increased
GSH levels and protected against oxidative glutamate toxicity (Lewerenz and Maher,
2009). Together these studies show that basal levels of eIF2α phosphorylation help
determine basal system xc- activity (Lewerenz and Maher, 2009).
Growth Factors and Other Peptides
Growth factors and other peptides also regulate system xc- activity. Our lab has
previously shown that FGF-2 upregulates system xc- activity in astrocytes; upregulation
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was through FGF receptor 1 (FGFR1) and both the MEK/ERK and PI3-kinase pathways
(Liu et al., 2012). We have also shown that IGF-1 and TGF-β upregulate system xcactivity in dental pulp cells (Pauly et al., 2011).
Interleukin-1β (IL-1β) upregulates system xc- activity, specifically in cortical
astrocytes, through the IL-1 receptor (Jackman et al., 2010). The same lab also showed
that IL-1β upregulates GSH synthesis in astrocytes through nuclear factor-kappaB (NFκB) activity (He et al., 2015). While the 5’ end of the xCT gene contains a NF- κB
binding site (Sato et al., 2001), there is no direct evidence that IL-1β increases system xcactivity through the NF- κB pathway.
Similar to FGF-2 and IL-1β, pituitary adenylate cyclase-activating polypeptide
(PACAP) increases system xc- activity in cortical cultures. The pathway has been
partially determined. Applying PACAP for at least 6 hours induces system xc- activity
through VPAC1R, the vasoactive intestinal peptide (VIP) receptor, and a protein kinase
A (PKA)-dependent pathway (Resch et al., 2014). It has also been shown that inhibiting
PKA decreases system xc- activity in ex vivo striatal punches rapidly (Baker et al. 2002).
The differences in the time course of the two studies suggest that PKA may regulate
system xc- through multiple mechanisms (Massie et al., 2015). More direct evidence is
needed to understand the mechanism(s) behind PKA’s regulation of system xcexpression and activity.
Intracellular GSH levels can also increase system xc- activity. Depleting GSH
from astrocytes that have been treated with dibutyryl-cyclic AMP (dbcAMP) upregulates
system xc- activity. The exact mechanism is unknown, but it is independent of the Nrf2
pathway (Seib et al., 2011).
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Potential Role of System xc- in Brain Disorders
Oxidative stress and excitotoxicity are two of the key mechanisms in many
neurodegenerative diseases (Coyle and Puttfarcken, 1993; Simonian and Coyle, 1996;
Doble, 1999). The dual nature of system xc- suggests that it may provide antioxidant
protection during times of increased oxidative stress; however, by releasing glutamate
into the extrasynaptic space it also has the potential to contribute to neuronal death
through excitotoxicity. In this thesis we analyze the function of system xc- in the SOD1G93A mutant mouse model of ALS. However, the pathology of many neurodegenerative
diseases suggests that system xc- may also play an important role in them, so we briefly
review what is known about system xc- in these diseases as well.
Amyotrophic lateral sclerosis
ALS is the most common paralytic disease in adults, characterized by the loss of
motor neurons in the motor cortex, brainstem, and spinal cord, which results in loss of
motor function. It is believed that approximately 10% of ALS cases are inherited, while
the majority of cases are sporadic, and are of unknown cause. The mutation involved in
approximately 10-20% of genetic cases involves copper/zinc superoxide dismutase type 1
(SOD-1). Interestingly, silencing the SOD-1 gene does not produce ALS symptoms
(Shefner et al., 1999), but rather it appears to be a gain-of-function mutation as mice
expressing the human SOD-1 mutation do develop ALS-like symptoms (Gurney et al.
1994). Also, motor neuron death occurs through a non-cell autonomous mechanism with
glial cells (Clement et al., 2003; Boillée et al., 2006; Yamanaka et al., 2008). Although it
is unclear what causes ALS, it is clear that oxidative stress is a key mechanism involved
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in the pathology of the disease. Elevated levels of protein carbonyl groups, markers of
oxidative damage, have been found in post mortem tissue from ALS patients (Bowling et
al., 1993; Ferrante et al., 1997); and increased production of both oxygen and hydroxyl
free radicals have been found in transgenic mice with the human SOD1-G93A mutation
(Yim et al., 1996; Bogdanov et al., 1998; Liu et al., 1998).
Another key mechanism in the pathology of ALS is excitotoxicity. Elevated
levels of glutamate have been found in patients with ALS (Spreux-Varoquaux et al.,
2002). Previous research has shown that the increase in glutamate levels may be
attributed to a decrease in EAAT2/GLT-1, the main mechanism by which glutamate is
taken up out of the extrasynaptic space and into astrocytes. Decreased levels of GLT-1
have been reported in both the brain and spinal cord in post mortem tissue of ALS
patients (Rothstein et al., 1995) and in the ventral horn of SOD1-G93A transgenic rat and
mouse spinal cords (Canton et al., 1998; Warita et al., 2002; Bendotti et al., 2001). While
impaired glutamate transports seem to play an important role in the increased
extracellular glutamate levels seen in ALS, decreases in the glutamate transporter do not
appear until after the onset of symptoms in the mouse models and, therefore, are probably
not the primary cause of motor neuron loss (Canton et al., 1998; Warita et al., 2002;
Bendotti et al., 2001).
Elevated levels of glutamate could also occur as a result of increased system xcfunction and/or expression. Prior to our work done in ex vivo slice from SOD1-G93A
mice (Chapter II), the function of system xc- had not been assessed in ALS. Following
our study, system xc- function was also examined in the SOD1-G37R mouse model, a
much slower progression model of the disease. In the SOD1-G37R model xCT mRNA
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increased in the spinal cord over the course of the disease, specifically in microglia
(Mesci et al., 2015). Post-mortem spinal cord tissue from ALS patients also expressed
xCT mRNA that correlated with a marker for macrophage inflammation (Mesci et al.,
2015). Interestingly, deletion of xCT in the SOD1-G37R mouse led to an earlier onset of
symptoms followed by a prolonged symptomatic stage; at end stage of the disease there
were more surviving motor neurons (Mesci et al., 2015). The implications of the findings
in this study will be discussed further in the context of our discoveries in the SOD1G93A model (Chapter V).
Alzheimer’s disease
AD is the most common neurodegenerative disease. It is characterized by
degeneration in the hippocampus and cerebral cortex, which leads to impairments in
memory and cognition. Two of the main hallmarks of AD are the formation of
extracellular Aβ plaques and intracellular tangles of phosphorylated tau protein. Aβ is
derived from cleavage of the amyloid precursor protein (APP) (Selkoe, 1994) and
abnormal accumulation can lead to cell death by inducing oxidative stress (Varadarajan et
al., 2000; Butterfield et al. 2002; Butterfield and Lauderback, 2002).
Reactive microglia are found in the plaques of AD patients. Therefore, the first
studies that analyzed system xc- function in AD looked at the effects of soluble APP
(sAPP) and Aß1-40 on primary microglia cultures. Both sAPP and Aß1-40 peptide
increased glutamate release from microglia through system xc- (Barger and Basile, 2001;
Qin et al., 2006). The sAPP induced increase in glutamate release caused increased
calcium elevation in hippocampal neurons and compromised their synaptic density
(Barger and Baile, 2001), while Aß1-40 induced glutamate release caused NMDA receptor
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mediated excitotoxicity and masked the protective effects of microglia release of
apolipoprotein E (apoE) (Qin et al., 2006). These studies suggest that increased system
xc- activity in microglia has detrimental effects on neurons in AD. Another study,
however, found that increasing system xc- by activating the eIF2α-ATF4-AARE pathway
made PC12 cells more resistant to Aß1-42 peptide toxicity (Lewerenz and Maher, 2009).
To date there are only a couple of in vivo studies that have assessed system xc- in
AD. In 18-month old AßPP23 mice expression of xCT, as assessed by western blot, is
increased in the cortex. At this same time point, GLT-1 expression was decreased and
there were increased levels of extracellular glutamate (Schallier et al., 2011). Transgenic
mice expressing human APP and wild-type mice injected with Aβ1-40 have increased xCT
mRNA levels in microglia in amyloid plaques (Qin et al., 2006).
There have been some AD studies assessing the effects of N-acetylcysteine
(NAC). NAC is a pro-cysteine drug that drives system xc- activity (Kupchik et al. 2012).
In one double-blind study where AD patients were given NAC, they showed beneficial
trends in all areas tested, particularly in cognitive tasks (Adair et al., 2001). NAC
pretreatment was also shown to protect SHS5Y neuroblastoma cells from Aβ1-42 and
Aβ25-35 (Olivieri et al., 2001), an effect associated with decreased Aβ secretion and tau
phosphorylation; they did not assess system xc- function in these cells. Therefore, while
these studies show beneficial effects of NAC in AD none of those benefits have been
directly linked to increased system xc- activity. Further studies using xCT knockout mice
in AD mouse models may help to better clarify the role of system xc- in AD.
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Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disease characterized by a loss of
dopaminergic neurons in the substantia nigra. Loss of dopaminergic neurons leads to a
progressive loss of motor function; symptoms include stiff gait, tremors, impaired
balance, slow movement, and eventually muscle atrophy (Beitz, 2014). While the cause
of dopaminergic cell death is unknown, oxidative stress (Hwang, 2013) and
excitotoxicity (Caudle and Zhang, 2009) play a role in the pathology of PD.
Determining the effects of system xc- in PD models has led to mixed results. In
the hemi-Parkinson rat model, injection of 6-hydroxydopamine (6-OHDA) caused an
ipsilateral increase in xCT protein in the striatum three weeks after injection; twelve
weeks after injection xCT levels were back down to normal (Massie et al., 2008). In a
follow up study dopaminergic neurons in the substantia nigra pars compacta were
protected from 6-OHDA injection in xCT-/- mice compared to wild-type mice (Massie et
al., 2011). GSH levels were unaffected and oxidative stress was not elevated in the xCT/- mice; however, extracellular glutamate levels were significantly reduced (Massie et al.,
2011). Taken together the data suggests that system xc- may contribute to the
neurodegeneration seen in PD. A more recent study has yielded different results in the 6OHDA model of PD. The anti-epileptic drug levetiracetam (LEV) increased xCT
expression and GSH levels in astrocytes cultured from the striatum. Culture medium
taken from LEV treated astrocytes was able to protect dopaminergic neurons from 6OHDA toxicity, an affect that was blocked by xCT inhibitor SSZ (Miyazaki et al., 2016).
In vivo LEV also increased xCT expression in striatal astrocytes and significantly
decreased dopaminergic cell loss in mice injected with 6-OHDA (Miyazaki et al., 2016).
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The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD has also
yielded different results regarding the actions of system xc-. xCT expression was
increased in the striatum, but decreased in the substantia nigra pars compacta following
MPTP injection (Bentea et al., 2015). Also, MPTP injection resulted in similar levels of
dopaminergic cell loss and similar behavioral deficits in both xCT-/- mice and wild-type
mice (Bentea et al., 2015), which suggests system xc- does not affect neurodegeneration
of dopamine neurons. Given the differences seen between different models of PD and
even within the same model, further studies need to be performed in order to gain a better
understanding of system xc-’s role in PD.
Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune demyelinating disease. Pathology of
the disease includes white matter scar formation, inflammation, disruption in the blood
brain barrier, and glutamate dysregulation (Werner et al., 2001; Minagar and Alexander,
2003; Goldenberg, 2012). Dysregulation of glutamate contributes to the death of
oligodendrocytes, myelin-producing cells in the CNS, however the source of this
glutamate is unknown (Werner et al., 2001).
In microglia-oligodendrocyte cocultures, activation of microglia by
lipopolysaccharide (LPS) caused an increase in glutamate release through system xc-,
resulting in increased extracellular glutamate and oligodendrocyte toxicity (Domercq et
al., 2007). Similarly, CD4+ T helper cells provoke microglia to release glutamate
through system xc- resulting in oligodendrocyte excitotoxicity (Evonuk et al., 2015).
Microglia cells from the spinal cord of rats treated with experimental autoimmune
encephalomyelitis (EAE), a model of MS, have increased xCT mRNA and protein levels
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(Pampliega et al., 2011). This finding correlates with increased xCT mRNA levels found
in the leukocytes and optic nerve tissue from human MS patients (Pampliega et al.,
2011). Blocking system xc- in both the chronic and relapse-remitting EAE models of MS
decreased the clinical severity of the disease and decreased spinal cord demyelination
(Evonuk et al., 2015). Likewise, mice that contain inactive system xc- due to a mutation
in the xCT gene (sut/sut mice) are resistant to EAE treatment (Evonuk et al., 2015).
Together this data suggests that increased glutamate release though system xc- may
contribute to the degeneration of oligodendrocytes and that decreasing system xc- activity
may be a therapeutic target for the treatment of MS.
Huntington’s Disease
Huntington’s disease (HD) is a fatal neurodegenerative disease caused by a
polyglutamine expansion in the huntingtin (htt) gene. This autosomal dominant mutation
leads to the death of GABAergic medium spiny neurons, mainly in the striatum; the
mechanism of this selective neuronal death is unknown (Vonsattel and DiFiglia, 1998).
However, there is strong evidence that there is mitochondrial dysfunction, resulting in
defects in energy metabolism, oxidative stress, and excitotoxicity (Browne and Beal,
2004).
Little is known about system xc- activity in HD. In the striatal cell line
STHdhQ111/Q111, a model of HD, system xc- mRNA levels and protein expression were
decreased, which resulted in decreased system xc- function (Frederick et al., 2014).
These cells also have decreased GSH levels, increased levels of ROS, and are more
sensitive to oxidative stress caused by DEM (Frederick et al., 2014). System xc- mRNA
and protein levels were also decreased in the striatum of R6/2 mutant htt exon 1
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transgenic mice, another model of HD (Frederick et al., 2014). Administration of NAC
in the R6/1 model of HD resulted in delayed symptom onset and progression of motor
deficits (Wright et al., 2015). The mechanism behind the benefits of NAC was not
determined. Ceftriaxone, an antibiotic that increases xCT and EAAT2/GLT-1 expression
(Lewerenz et al., 2009), also attenuated the R6/2 behavioral phenotype (Miller et al.,
2008). The authors attributed ceftriaxone’s positive effects to restoring basal levels of
glutamate in the striatum through increased in GLT-1 expression, however, they did not
assess xCT levels, so an increase in system xc- activity contributing to the effects cannot
be ruled out.
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CHAPTER II
REGULATION OF SYSTEM XC- IN THE SOD1-G93A MOUSE MODEL OF ALS
Abstract
The cystine/glutamate antiporter (system xc-) is critical for the generation of the
antioxidant glutathione by transporting cystine into the cell. At the same time, system xcalso releases glutamate, which can potentially lead to excitotoxicity. The dual actions of
system xc- make it of great interest in any disease, like amyotrophic lateral sclerosis
(ALS), in which there is evidence of the involvement of both oxidative stress and
excitotoxicity. The present study investigated the regulation of system xc- in the spinal
cord of the SOD1-G93A transgenic mouse model of ALS. In spinal cord slices of 70 day
old SOD1-G93A transgenic mice cystine uptake by system xc- was significantly
increased compared to age matched nontransgenic mice; but it was not significantly
different at 55, 100, or 130 days. The spinal cord slices of 70 day old SOD1-G93A
transgenic mice also showed significantly increased glutamate release in the presence of
cystine. In contrast, in glial cells cultured from postnatal day 1-3 mice there was no
difference in cystine uptake in cultures from SOD1-G93A mice; and it was actually less
when oxidative stress was induced by exposure to iron. D-aspartate uptake through
excitatory amino acid transporters (EAATs), the main mechanism by which glutamate is
cleared from the extracellular space was also examined. In spinal cord slices of 70 day
old SOD1-G93A mice no change in D-aspartate uptake was found. Together, these
findings suggest that at 70 days of age, SOD1-G93A transgenic mice have increased
system xc- activity, but no change in EAAT function. These results raise the possibility
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that excitotoxicity in the SOD1-G93A transgenic mouse, at least at early time points, may
be due to increased system xc- activity and not decreased EAAT function.
Introduction
Amyotrophic lateral sclerosis is the most common paralytic disease in adults,
characterized by the loss of motor neurons in the motor cortex, brainstem, and spinal
cord, which results in atrophy and loss of motor function. It is believed that
approximately 10% of ALS cases are inherited, while the majority of cases are sporadic.
The mutation involved in approximately 10-20% of genetic cases involves copper/zinc
superoxide dismutase type 1 (SOD-1). Interestingly, silencing the SOD-1 gene does not
produce ALS symptoms (Shefner et al., 1999), but mice expressing the human SOD-1
mutation do develop ALS like symptoms (Gurney et al., 1994). Although it is unclear
what causes ALS, it appears that oxidative stress plays a key role in the pathology of the
disease. Elevated levels of protein carbonyl groups, markers of oxidative damage, have
been found in post mortem tissue from ALS patients (Bowling et al., 1993; Ferrante et
al., 1997); and increased production of oxygen free radicals have been found in
transgenic mice with the human SOD1-G93A mutation (Yim et al., 1996; Bogdanov et
al., 1998; Liu et al., 1998).
Another key mechanism in the pathology of ALS is excitotoxicity. Elevated
levels of glutamate have been found in patients with ALS (Rothstein et al., 1990; SpreuxVaroquaux et al., 2002). Previous research has shown that the increase in glutamate
levels may be attributed to a decrease in the high affinity glutamate transporter
(EAAT2/GLT-1), the main mechanism by which glutamate is taken up from the
extrasynaptic space and into astrocytes. Decreased levels of EAAT2/GLT-1 have been
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reported in both the brain and spinal cord of post mortem tissue of ALS patients
(Rothstein et al., 1995) and in the spinal cord of SOD1-G93A transgenic rats (Howland et
al., 2002) and mice (Bendotti et al., 2001).
The cystine/glutamate antiporter (system xc-) is a sodium-independent amino acid
transporter that may play a key role in both oxidative stress and excitotoxicity due to its
dual function. System xc- mediates the transport of cystine into the cell in exchange for
releasing glutamate into the extrasynaptic space. After being taken up into the cell,
cystine is reduced to cysteine and used in the synthesis of glutathione (GSH), an
abundant and important antioxidant in the brain (Dringen and Hirrlinger, 2003). This
activity occurs mainly on non-neuronal cells and the release of GSH by these cells can be
protective to neurons (Shih et al., 2003).
Not only does system xc- act to prevent oxidative stress, but such stress appears to
be the main trigger for its upregulation. Oxidative stress induced by exposure of Muller
glial cells to xanthine/xanthine oxidase causes an upregulation of system xc- activity
(Mysona et al., 2009). Also, oxidative stress and nitric oxide upregulates system xcactivity in a retinal ganglion cell line (RGC-5) (Dun et al., 2006), while oxidative stress
induced by exposure to diethylmaleate increases system xc- function in human glioma
cells (Kim et al., 2001). Thus, it appears that upregulation of system xc- may act as a
mechanism of cellular protection against oxidative stress.
In contrast to the possible neural protective mechanism of system xc- against
oxidative stress, it is known that glutamate release via system xc- can cause excitotoxicity
and lead to neuronal death. The strongest evidence comes from studies involving glia.
Glutamate release via system xc- from microglia kills cerebellar granule cells (Piani and
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Fontana, 1994). Also, activation of microglia by amyloid-β causes increased glutamate
release and neuronal death in cortical cultures (Qin et al., 2006). System xc- on
astrocytes may also play a role in neuronal death. Activation of astrocytes with IL-1β
leads to increased system xc- mediated glutamate release causing enhanced excitotoxicity
of cortical neurons exposed to hypoxia or glucose deprivation (Fogal et al., 2007;
Jackman et al., 2010).
Due to the complex nature of the pathology of ALS, and the ability of system xcto alter both oxidative stress and excitotoxicity, the current studies were designed to
evaluate the function of system xc- in spinal cord slices of the SOD1-G93A transgenic
mouse. Since oxidative stress is a main factor that can lead to the upregulation of system
xc- it was our prediction that system xc- would be upregulated in these mice. We also
evaluated the function of EAATs since no functional analysis of EAATs has been
previously performed in spinal cord slices of SOD1-G93A transgenic mice. Finally, we
cultured spinal cord glial cells to further characterize the regulation of system xc- in
SOD1-G93A mice.
Materials and Methods
Materials
Male B6SJL-TgN(SOD1-G93A)1Gur/J and female B6SJLF1/J mice were
obtained from Jackson Laboratory (Bar Harbor, ME). 14C-cystine was from PerkinElmer
(Waltham, MA). All other chemicals were from Sigma (St. Louis, MO).
Animals
Male B6SJL-TgN(SOD1-G93A)1Gur/J autosomal hemizygous mice were bred
with female B6SJLF1/J hybrid non-affected control mice. At 3 weeks of age, pups were

49
separated and housed individually. Mice were handled in accordance with a protocol
approved by our institutional animal care committee.
Genotyping
The presence of the human G93A transgene was confirmed using PCR of DNA
extracted from ear punch samples or tail snips. Ear punches and tail snips were dissolved
in 50mM Tris, 2mM NaCl, 10mM EDTA, 1% sodium dodecyl sulfate (SDS), and
1mg/mL Proteinase K in a 56ºC water bath. They were then heat shocked for 8 minutes
at 100ºC and immediately put on ice. 250µL of water was added and samples were
stored overnight at 4ºC. PCR was then performed to identify transgenic littermates
(Transgene forward primer: CAT CAG CCC TAA TCC ATC TGA; Transgene reverse
primer: CGC GAC TAA CAA TC A AAG TGA).
Neurological Scoring
Neurological scoring was performed three times a week, starting around day 55
and was performed as recommended by the Jackson Labs guide “Working with ALS
mice”. The score criteria was as follows:
Score of 0: Full extension of hind legs away from lateral midline when mouse is
suspended by its tail, and mouse can hold this for two seconds, suspended two
to three times.
Score of 1: Collapse or partial collapse of leg extension towards lateral midline or
trembling of hind legs during tail suspension.
Score of 2: Toes curl under at least twice during walking of 12 inches, or any part of foot
is dragging along cage bottom/table.
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Score of 3: Rigid paralysis or minimal joint movement, foot not being used for
generating forward motion.
Score of 4: Mouse cannot right itself within 30 seconds after being placed on either side.
A score of 0 is pre-symptomatic. A score of 1 is early symptomatic. A score of 2 or 3 is
symptomatic and a score of 4 results in termination.
Spinal Cord Removal and Slice Preparation
Experiments were performed using spinal cord slices from transgenic and
littermate nontransgenic mice. Male and female mice of various ages were euthanized by
cervical dislocation following isoflurane anesthesia. The entire vertebral column from
just below the skull to the hips was removed and placed into ice cold slice buffer (119
mM NaCl, 3mM KCl, 1.4mM KH2PO4, 2.7mM MgSO4, 26mM NaHCO3, 7.8mM
glucose, 2.4mM CaCl2). A 16-gauge beveled needle was inserted into the lumbar end of
the column and the spinal cord was ejected from the vertebral column by injecting slice
buffer into the vertebral column (Meikel and Martin, 1981). Using a McIlwain tissue
chopper, the spinal cord was cut transversely into 400µm slices and placed onto nylon
mesh platforms in ice cold slice buffer. Slices from the cervical, thoracic, and lumbar
levels of the spinal cord were used for experiments. Slices were then incubated in slice
buffer with 95% O2 and 5% CO2 at 37°C for 30 minutes before uptake or release
experiments. Alternating slices were used for the different experimental conditions, with
2-3 slices for each condition being used to generate each “n” value; multiple animals
were used.
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Spinal Cord Cell Culture
Astrocyte-enriched glial cultures from the spinal cord were prepared from
postnatal day 1-3 SOD1-G93A mice as previously described, with modifications
(Kerstetter and Miller, 2012). Briefly, dissociated spinal cord cells were plated on 24well plates (2.0 cm2 surface area per well) coated with poly-D-lysine and laminin in
Eagles’ Minimal Essential Medium (MEM, Earle’s salts, supplied glutamine-free)
supplemented with 5% (v/v) heat-inactivated horse serum, 5% (v/v) fetal bovine serum, 2
mM glutamine and D-glucose (total 21 mM). Cultures were maintained in humidified
5% CO2 incubators at 370C with experiments performed on cultures DIV 13-15.
14

C-Cystine Uptake
Radiolabeled cystine uptake into spinal cord slices was measured by exposure to

slice buffer containing 14C-cystine (0.15µCi/ml) for 30 minutes at 37°C, in the presence
or absence of 300µM of the system xc- inhibitor sulfasalazine (SSZ). The slices were
then washed for 2 minutes in ice cold slice buffer and dissolved in 250µL 1% SDS. A
100µL aliquot was removed and added to scintillation fluid for counting. Another 100µL
aliquot was removed to measure cellular protein levels using the BCA assay.

14

C-cystine

uptake values were normalized to cellular protein levels.
Radiolabeled cystine uptake in spinal cord glial cultures was performed as
previously described, with modifications (Liu et al., 2009). Cultures were exposed to
media with or without 100µM iron sulfate for 24 hours. After the drug exposure cultures
were washed into HEPES buffered saline solution and immediately exposed to 14Ccystine (0.025µCi/mL, 200nM total cystine) for 20 minutes. Following 14C-cystine
exposure, cultures were washed with ice cold HEPES buffered saline solution and
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dissolved in 250µl warm sodium dodecyl sulfate (0.1%). An aliquot (200µl) was
removed and added to scintillation fluid for counting. A 30µL aliquot was removed to
measure cellular protein levels using the BCA assay.

14

C-cystine uptake values were

normalized to cellular protein levels.
Analysis of Glutamate Release
To measure glutamate released from spinal cord slices, slices were exposed to
slice buffer in the presence or absence of 100µM cystine for 30 minutes at 37°C. The
slices were then removed and dissolved in 250µL of 1% SDS. A 100µL aliquot was
removed for the BCA protein assay. Also, the media the slices were bathed in was
collected and analyzed for glutamate by HPLC (Agilent 1100), using a Hypersile-ODS
reverse phase column, and ultraviolet detection at a 254nm wavelength, as previously
described (Rush et al., 2010). Briefly, 200µL of media was derivatized with 100µL of
phenylisothiocyanate (PITC), methanol, triethylamine (TEA) and dried under vacuum.
Samples were then reconstituted in solvent consisting of 0.14M sodium acetate, 0.05%
TEA, 6% acetonitrile, and brought to a pH of 6.4 with glacial acetic acid. The solvent
was also used as the mobile phase, with the column being washed in 60% acetonitrile and
40% water between each sample run. Media glutamate concentrations were calculated by
normalizing to glutamate standards ranging from 1-100µM. Glutamate values were then
normalized to cellular protein levels.
3

H-D-Aspartate Uptake
To assess EAAT function, uptake of radiolabeled D-aspartate into spinal cord

slices was measured. Slices were exposed to slice buffer containing 3H-D-aspartate
(0.25µCi/ml) for 30 minutes in the presence or absence of 100µM of the general EAAT
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inhibitor DL-threo-β-Benzyloxyaspartic acid (TBOA). The slices were then washed for 2
minutes in ice cold slice buffer and dissolved in 250µL 1% SDS. A 100µL aliquot was
removed and added to scintillation fluid for counting. Another 100µL aliquot was
removed to measure cellular protein levels using the BCA assay. 3H-D-aspartate uptake
values were normalized to cellular protein levels.
EAAT function was also assessed in spinal cord glial cultures using radiolabeled
D-aspartate. Cultures were exposed to media with or without 100µM iron citrate for 24
hours. Cultures were then washed with HEPES buffered saline solution and immediately
exposed to 3H-D-asparate (0.25µCi/ml) for 20 min. Following 3H-D-aspartate exposure,
cultures were washed, dissolved, and scintillation counted as for 14C-cystine studies. A
30µL aliquot was removed to measure cellular protein levels using the BCA assay. 3HD-asparate uptake values were normalized to cellular protein levels.
Assay of neuronal death
Cell death was assessed in spinal cord glia cultures by the measurement of lactate
dehydrogenase (LDH), released from damaged or destroyed cells, in the extracellular
fluid 24 hours after exposure to varying concentrations of iron citrate. Control LDH
levels were subtracted from insult LDH values, and results normalized to 100% cell death
caused by 10 µM A23187. Control experiments have shown previously that the efflux of
LDH occurring from either necrotic or apoptotic cells is proportional to the number of
cells damaged or destroyed (Lobner, 2000; Koh and Choi, 1987).
l2’,7’-dichlorofluorescein (DCF) assay of oxidative stress
Oxidative stress was assayed by measuring DCF oxidation using a fluorescent
plate reader following a modification of a previous method (Wang and Joseph, 1999;
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Lobner et al., 2007). Briefly, cultures were exposed to 100µM iron citrate for the
indicated time, after which they were exposed to 5-(and –6)-carboxy-2’7’dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (10µM). The carboxyH2DCFDA is de-esterified within cells to form a free acid that can then be oxidized to the
fluorescent 2’7’-dichlorofluorescein (DCF). After a 1-hour exposure to carboxyH2DCFDA, cultures were washed 3 times with culture media lacking serum and
dissolved in DMSO. A 200µL aliquot was taken and fluorescence was measured using a
Fluoroskan Ascent fluorescence plate reader (ThermoLabsystems). The excitation filter
was set at 485 nm and emission filter at 538 nm. A 30µL aliquot was removed to
measure cellular protein levels using the BCA assay. Background fluorescence (no
carboxy-H2DCFDA added) was subtracted and the results normalized to cellular protein
levels.
Monochlorobimane (MCB) assay of cellular reduced GSH
Cellular GSH levels were measured by MCB fluorescence. MCB forms a
fluorescent compound when it reacts with GSH through a reaction catalyzed by
glutathione-S-transferase. As previously described (Pauly et al., 2011) with modification,
cultures were exposed to 100µM iron citrate for the indicated time, after which they were
exposed to MCB (10µM). After 30 minutes the cultures were washed with ice cold
HBBSS and dissolved in DMSO. A 200µL aliquot was taken and excited at a
wavelength of 355 nm and emission measured at a wavelength of 460 nm using a Thermo
Labsystems Fluoroskan microplate reader. A 30µL aliquot was removed to measure
cellular protein levels using the BCA assay. Background (no MCB added) was
subtracted and the results normalized to cellular protein levels.
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Statistical analysis
Differences between test groups were examined for statistical significance by
means of a t-test and one-way ANOVA followed by the Bonferroni post-hoc analysis,
with a p-value <0.05 being considered significant.
Results
We first tested whether cystine uptake was altered in spinal cord slices in mice
prepared from SOD1-G93A compared to nontransgenic littermate mice. Cystine uptake
was the same in 55 day old mice, but in 70 day old mice there was significantly higher
cystine uptake in the SOD1-G93A mice. This difference disappeared in the 100 day old
mice (Figure 2.1). At all three of these time points mice were presymptomatic
(neurological score of 0). Cystine uptake was also measured in 130 day old mice, which
were early symptomatic (each with a neurological score of 1). Similar to the 100 day old
mice, there was no significant difference in cystine uptake in the 130 day old mice.
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Figure 2.1 14C-cystine uptake in spinal cord slices of SOD1-G93A mice is significantly
increased compared to nontransgenic (NonTG) mice at 70 days, but not at 55, 100, or 130
days of age. Bars show the counts per minute (cpm) of radiolabeled cystine per µg
protein (mean ± s.e.m, n=10-16; 2-5 animals were used for each experimental group)
during a 30 minute uptake assay in spinal cord slices. * indicates a significant difference
within an age group, t-test (p < 0.05).
There are multiple mechanisms by which cystine may enter cells, to determine if
the change in uptake was due to increased system xc- activity, we tested the inhibitor of
this system, sulfasalazine (SSZ). SSZ blocked about 30% of cystine uptake in
nontransgenic mice, but completely blocked the increased cystine uptake in 70 day old
SOD1-G93A mice (Figure 2.2A). Graphing only the SSZ dependent cystine uptake
showed that it was this component that was elevated in the SOD1-G93A mice (Figure
2.2B).
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Figure 2.2 The increased 14C-cystine uptake in spinal cord slices of SOD1-G93A mice is
through system xc-. A) At 70 days of age, 14C-cystine uptake into spinal cord slices is
significantly blocked by the system xc- inhibitor, sulfasalazine (SSZ) in both SOD1G93A and NonTG mice. B) The amount of cystine uptake through system xc- is
significantly higher at 70 days in SOD1-G93A mice compared to NonTG mice. Bars
show the cpm of radiolabeled cystine per µg protein (mean ± s.e.m, n=16-20; 3-4 animals
were used for each experimental group) during a 30 minute uptake assay in the presence
or absence of 300µm SSZ. * indicates a significant difference from the NonTG mice. #
indicates a significant difference within a group, t-test (p < 0.05).
Since each time system xc- transports one cystine molecule into the cell it also
transports one glutamate molecule out of the cell, it would also be expected to increase
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glutamate release in the slices from 70 day old SOD1-G93A mice. Under conditions
with no added extracellular cystine, the glutamate accumulation was slightly elevated in
slices from SOD1-G93A mice. However, with 100µM cystine present in the media, there
was significantly greater glutamate accumulation in the media from SOD1-G93A mouse
slices (Figure 2.3).

Figure 2.3 70 day old SOD1-G93A mice have higher glutamate release from spinal cord
slices than NonTG mice; this release can be driven by cystine. Bars show the
extracellular glutamate levels per µg protein (mean ± s.e.m, n=4-6; 2-3 animals were
used for each experimental group) released from spinal cord slices during a 30 minute
release assay in the presence or absence of 100µM cystine. * indicates a significant
difference from the NonTG mice. # indicates a significant difference within a group, ttest (p < 0.05).
It is well known that glutamate uptake is decreased in both ALS patients and
SOD1-G93A mice. However, glutamate uptake in spinal cord slices has not previously
been tested in any ALS model. We found that glutamate uptake, measured by 3H-Daspartate uptake, was not changed in either the presymptomatic 55, 70, or 100 day old
SOD1-G93A mice or in the early symptomatic 130 day old mice (Figure 2.4). To
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determine whether the D-aspartate uptake was actually measuring transport by EAATs
we tested the effect of the general EAAT inhibitor TBOA. TBOA blocked about 80% of
3

H-D-aspartate uptake in both nontransgenic and SOD1-G93A 70 day old mice (Figure

2.5A) and there was no difference in the amount of TBOA dependent uptake (Figure
2.5B).

Figure 2.4 There is no significant difference in 3H-D-aspartate uptake between NonTG
and SOD1-G93A mice at 55, 70, 100, or 130 days of age (t-test performed). Bars show
the cpm of radiolabeled D-aspartate per µg protein (mean ± s.e.m, n=11-16; 2-5 animals
were used for each experimental group) during a 30 minute uptake assay in spinal cord
slices.
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Figure 2.5 3H-D-aspartate uptake through EAATs is not significantly different between
NonTG and SOD1-G93A mice. A) At 70 days of age, 3H-D-aspartate uptake into spinal
cord slices is significantly blocked by the excitatory amino acid transporter (EAAT)
inhibitor, DL-threo-β-Benzyloxyaspartic acid (TBOA) in both NonTG and SOD1-G93A
mice. B) The amount of D-aspartate uptake mediated by EAATs is not significantly
different at 70 days in SOD1-G93A mice compared to NonTG mice. Bars show the cpm
of radiolabeled D-aspartate per µg protein (mean ± s.e.m, n=8-11; 3-4 animals were used
for each experimental group) taken up during a 30 minute uptake assay in the presence or
absence of 100µm TBOA. * indicates a significant difference, t-test (p < 0.05).
Astrocytes carrying the SOD1-G93A mutation have been shown to promote
motor neuron degeneration (Cassina et al., 2008; Fritz et al., 2013; Papadeas et al.,
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2011). Since system xc- is mainly found on astrocytes (Fritz et al., 2013) and has the
potential to lead to excitotoxicity through increased glutamate release, we wanted to
further characterize system xc- and its regulation in SOD1-G93A astrocyte-enriched glial
spinal cord cells. First, we tested whether cystine uptake was altered compared to
nontransgenic littermates. Cystine uptake was the same under control conditions (Figure
2.6). In order to see if cystine uptake changed in response to oxidative stress we
challenged the cells with 100µM iron citrate (Fe). As expected, cystine uptake increased
significantly. Interestingly, the increase in SOD1-G93A mice was significantly lower
than in nontransgenic littermates. Based upon what we observed in the spinal cord slices
from SOD1-G93A mice, these results were the opposite of what we hypothesized.

Figure 2.6 24-hour application of 100µM iron (Fe) increases 14C-cystine uptake more in
NonTG glial cells than in SOD1-G93A glial cells. Bars show the cpm of radiolabeled
14
C-cystine per µg protein (mean ± s.e.m, n=8-11) taken up during a 20 minute uptake
assay. * indicates a significant difference from control; # indicates a significant
difference from NonTG, t-test (p < 0.05).
To better understand what may be causing the difference in cystine uptake with
iron application seen between cultured SOD1-G93A spinal cord cells and nontransgenic
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littermates, GSH levels were measured in the presence and absence of 100µM Fe using
MCB, which fluoresces when it reacts with GSH. SOD1-G93A mice did not have altered
GSH levels under control conditions and 24-hour application of Fe significantly
decreased GSH levels in both SOD1-G93A mice and nontransgenic littermates (Figure
2.7).

Figure 2.7 100µM Fe causes a similar time-dependent decrease in cellular glutathione
levels in SOD1-G93A and NonTG glial cells. Cultures were exposed to 100µM Fe for 1,
6, 12, or 24 hours, after which cellular reduced glutathione was determined by MCB
fluorescence. Bars show MCB fluorescence normalized to cellular protein levels (mean
± s.e.m, n=8-16). * indicates significant difference from control, one-way ANOVA
(p < 0.05).
Another potential mechanism that may be causing the difference in cystine uptake
is the level of oxidative stress generated by iron. To assess this cellular oxidative stress
was measured with the l2’,7’-dichlorofluorescein (DCF), which fluoresces when
oxidized. Under control conditions, oxidative stress levels were the same; however, after
a 24-hour application of 100µM Fe, oxidative stress increased significantly more in the
nontransgenic littermate cultures than in SOD1-G93A cultures (Figure 2.8).
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Figure 2.8 100µM Fe causes greater increase in cellular oxidative stress as measured by
DCF fluorescence after 24-hour treatment in NonTG glial cells than in SOD1-G93A glial
cells. Bars show DCF fluorescence normalized to cellular protein levels (mean ± s.e.m,
n=8-16). * indicates significant difference from control, one-way ANOVA (p < 0.05);
# indicates significant difference from NonTg littermate at the same timepoint, t-test
(p < 0.05).
Since a large difference in oxidative stress induced by iron was observed, we
wanted to see if iron application had different effects on glial toxicity. 100µM Fe, which
is the concentration at which cystine uptake is altered, was not significantly toxic to
SOD1-G93A or nontransgenic glial cells. Surprisingly, even though oxidative stress was
higher in nontransgenic glial cells, a higher concentration of Fe (300µM) was more toxic
to SOD1-G93A glial cells (Figure 2.9).
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Figure 2.9 Greater toxicity is observed in SOD1-G93A cells treated with Fe than in
NonTG cells. Concentration response curve for 24 hr exposure to varying concentrations
of Fe on LDH release in primary glial cultures. Results are expressed as mean ± s.e.m
(n=8-16). * indicates significant difference from untreated control, one-way ANOVA
(p < 0.05).
Since we observed a difference in cystine uptake in the spinal cord glial cultures
compared to uptake in spinal cord slices, we wanted to determine if 3H-D-aspartate might
also be different. In contrast to what was observed in slices, cultured SOD1-G93A spinal
cord cells have significantly lower 3H-D-aspartate uptake under control conditions.
Interestingly, when challenged with 100µM Fe, 3H-D-aspartate uptake does not decrease
any further in SOD1-G93A mice (Figure 2.10).
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Figure 2.10 SOD1-G93A glial cells have lower 3H-D-aspartate uptake than NonTG cells
under control conditions. 24-hour application of 100µM Fe decreases 3H-D-aspartate
uptake in NonTG cells, but not in SOD1-G93A cells. Bars show the cpm of radiolabeled
14
C-cystine per µg protein (mean ± s.e.m, n=8-11) taken up during a 20 minute uptake
assay. * indicates a significant difference from NonTG control, t-test (p < 0.05).
Discussion
The present study is the first to evaluate the function of system xc- in the spinal
cord of any model of ALS. The role of system xc- in neuronal death is complex; it has
potentially damaging effects due to its ability to release glutamate while also having
potentially protective effects due to its ability to take up cystine, leading to enhanced
antioxidant capabilities. The relative contribution of excitotoxicity and oxidative stress in
ALS is not certain, and the potential for crosstalk between the two mechanisms exists.
For example, neuronal death induced by excitotoxicity can involve oxidative stress
(Dugan et al., 1996) and oxidative stress can induce glutamate release (Globus et al.,
1995). A previous study by Liu et al. (1998) showed that in the spinal cord of SOD1G93A transgenic mice there is a significant increase in oxidative stress beginning at day
60. In this study we observed a significant enhancement in cystine uptake in spinal cord
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slices from presymptomatic, 70 day old SOD1-G93A transgenic mice compared to
nontransgenic mice. This increase was not present at day 55 and was no longer present at
day 100. We also did not observe a difference in cystine uptake in 130 day old, early
symptomatic SOD1-G93A transgenic mice compared to their nontransgenic littermates.
The enhanced uptake in the 70 day SOD1-G93A was significantly blocked by
sulfasalazine (SSZ), the system xc- inhibitor, suggesting that the increase in cystine
uptake was through system xc-.
There was also increased cystine driven glutamate release in the spinal cord slices
of 70 day old SOD1-G93A mice. These findings suggest the possibility that the oxidative
environment found in the spinal cord of SOD1-G93A transgenic mice may upregulate
system xc-. This is a potential protective mechanism as it leads to increased cystine
uptake and glutathione synthesis. However, it will also cause increased glutamate release
which can induce excitotoxicity. To date the only FDA approved drug for the treatment
of ALS is the anti-excitotoxic compound, riluzole (Miller et al., 2002). The high
sensitivity of motor neurons to excitotoxicity is likely due to their expression of high
numbers of calcium permeable AMPA receptors (Carriedo et al., 1996) and low
expression of calcium binding proteins (Alexianu et al., 1994). Therefore, it is possible
that the combination of oxidative stress and the glutamate released by system xc-, along
with other potential factors, causes excitotoxicity in these mice.
The results in the SOD1-G93A astrocytes-enriched glial cells yield different
results than those observed in slices. In culture, no differences in radiolabeled cystine
uptake under control conditions were observed. Surprisingly, however, applying iron
caused a significantly larger increase in system xc- function in the nontransgenic cells
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than in the SOD1-G93A cells. Iron caused similar levels of GSH depletion in both
SOD1-G93A cells and nontransgenic cells. However, the DCF assay revealed that iron
caused a significantly larger increase in oxidative stress levels in nontransgenic cells,
which may explain the larger increase in system xc- function observed in nontransgenic
cells.
The SOD1-G93A mutation makes motor neurons more vulnerable to oxidative
stress (Bridges et al., 2012a; Papadeas et al., 2011) In the current study we observe that
the SOD1-G93A mutation also makes glial cells more vulnerable. 300µM Fe caused
toxicity in the SOD1-G93A cells; however, 300µM Fe did not cause toxicity in
nontransgenic cells, even though we observe higher levels of oxidative stress in these
cells. Therefore, while SOD1-G93A cells do appear to be more sensitive, it does not
appear to be due to increased oxidative stress. This finding is in agreement with a study
that found transfecting astrocytes with SOD1-G93A did not cause an increase in
oxidative stress (Boillée et al., 2006) . The increased toxicity in the SOD1-G93A glial
cells is not due to depleted GSH levels either, but rather through a mechanism we were
unable to detect.
It is interesting that system xc- function appears to decrease with age in
nontransgenic mice. To our knowledge, this is the first study measuring system xcactivity over a range of ages. Decreased system xc- function with age could potentially
be a contributing factor to the increased levels of oxidative stress observed with age
(Liochev, 2013).
Previous studies have shown decreased expression of EAAT2 in ALS animal
models. Decreased EAAT2 expression was found beginning at 14 weeks (98 days) in
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SOD1-G93A transgenic rats (Howland et al., 2002) and mice (Bendotti et al., 2001),
although another study involving these mice did not show a decrease until 35 weeks of
age (Warita et al., 2002). Also, studies of functional glutamate uptake using
synaptosomal preparations from SOD1-G93A transgenic mice did not indicate a
significant decrease in glutamate uptake until mice were 150 days old (Canton et al.,
1998). A potential mechanism for the decreased glutamate uptake observed in ALS is that
caspase 3 is able to cleave and inactivate EAAT2 (Boston-Howes et al., 2006). A
cleaved form of EAAT2 is found in spinal cords of SOD1-G93A mice (Boston-Howes et
al., 2006) and caspase 3 is highly activated in these mice at the time point of ALS-like
symptoms (Pasinelli et al., 2000). Since caspase 3 is activated in cells undergoing
apoptosis, these findings suggest that cell death may be triggered before the inactivation
of EAAT2.
In the current study we did not observe a significant decrease in radiolabeled Daspartate uptake in spinal cord slices from SOD1-G93A transgenic mice at 55, 70, 100, or
130 days of age. D-aspartate uptake was significantly blocked in both 70 day old SOD1G93A transgenic mice and nontransgenic mice by the EAAT inhibitor TBOA, showing
that the uptake of D-aspartate was through EAATs. However, the amount of D-aspartate
uptake blocked by TBOA was not significantly different between SOD1-G93A
transgenic mice or nontransgenic littermate mice, suggesting that there was no change in
EAAT function in SOD1-G93A transgenic mice at this age. Taken together, our results
that system xc- mediated glutamate release is increased long before any potential decrease
in glutamate uptake, suggest the possibility that this glutamate release may contribute to
early excitotoxicity in SOD1-G93A mice.
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However, the radiolabeled D-aspartate uptake results in cultured spinal cord glial
cells are quite different than what was observed in the spinal cord slices. In glial cell
cultures from SOD1-G93A mice there is a significant decrease in EAAT function in
control conditions. This would suggest that very early on these cells have an impaired
ability to handle glutamate, which could cause the increased levels of extracellular
glutamate and contribute to excitotoxicity seen in ALS patients. The reason why iron
application does not decrease EAAT function in SOD1-G93A cells further is unknown.
There have been a number of studies testing the effects of using N-acetylcysteine
(NAC) to drive system xc- as a potential treatment for ALS. NAC prevents increased
oxidative stress and mitochondrial dysfunction in human neuroblastoma cells (SH-SY5Y)
expressing the SOD1-G93A mutation (Beretta et al., 2003). In animal models of ALS the
results have been mixed. In the SOD1-G93A mouse, one study found that NAC
prolonged survival and delayed onset of motor impairment (Andreassen et al., 2000),
while in another study it did not alter survival or disease onset (Jaarsma et al., 1998).
There is one well controlled study using NAC in human ALS patients. In this
randomized, double-blind, controlled trial it was found that NAC provided a small, nonsignificant increase in survival, with no evidence of reduction in disease progression
(Louwerse et al., 1995). Interestingly, in subgroups of patients, those with disease of the
limbs onset showed increased survival, while those with bulbar onset had decreased
survival. This type of variability in effects may be expected given the dual actions of
driving system xc-. Supporting this view, riluzole provides greater survival promoting
benefit in ALS patients with bulbar symptoms (Bensimon et al., 1994; Zoccolella et al.,
2007), suggesting that excitotoxicity plays a greater role in these patients, which would
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be consistent with NAC having a negative effect in these patients. It is possible that
increased system xc- function may be particularly pronounced in these patients in which
case further driving system xc- could lead to excitotoxicity that overwhelms the benefit of
increased cystine uptake.
The data presented from spinal cord slices show there is enhanced system xcfunction occurring at 70 days of age in the SOD1-G93A mouse, possibly due to the
oxidative stress observed in these mice. This increased activity could be a protective
mechanism in that the increased cystine uptake would maintain glutathione levels even
under conditions of oxidative stress. Previously, it was found that in the spinal cord of
SOD1-G93A mice reduced glutathione levels were decreased at 110 days of age, but not
at 45 or 80 days (Chi et al., 2007). Interestingly, this study also found that oxidized
glutathione was increased at both 80 and 110 days of age. These results suggest that
glutathione production is increased at the 80 day timepoint, but high levels of oxidative
stress are causing the formation of increased oxidized glutathione. These results are
consistent with the elevated system xc- activity we found in 70 day old SOD1-G93A mice
being induced by oxidative stress and that upregulation acts as a mechanism to maintain
glutathione levels. However, the increased function of system xc- will also lead to
increased glutamate release, which may contribute to the eventual neurological deficits.
The studies done in spinal cord glial cells seem to conflict with the results we see
from spinal cord slices. The major difference in the ages of the mice used for these two
sets of experiments is likey a factor in these conflicting results. Spinal cord slice
experiments were performed in mice between the ages of 55 and 130 days old, while glial
cultures were made from postnatal 1-3 day old pups. Major changes occur in the SOD1-
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G93A mice as they age that cannot be replicated in culture. These are not the only
discrepancies seen between in vitro and in vivo work done in SOD1-G93A mice.
Tortarolo et al. (2004) saw a decrease in GLT-1 expression and function in primary
astrocytes only four days after they are transfected with the SOD1-G93A gene.
However, in vivo decreases in GLT-1 expression and function are not seen in the SOD1G93A mouse until at least the symptomatic stages of the disease (Tortarolo et al., 2004) .
The discrepancies seen between these studies highlight the differences between work
done in vitro and in vivo. While in vitro studies are useful to determine mechanisms, the
limitations of work done in vitro must be taken into consideration when translating them
in vivo. With this in mind, further studies will be required to determine the net effects of
system xc- activity in the SOD1-G93A mouse model and in human ALS patients.
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CHAPTER III
REGULATION OF SYSTEM XC- BY PHARMACOLOGICAL
MANIPULATION OF CELLULAR THIOLS
Abstract
The cystine/glutamate exchanger (system xc-) mediates the transport of cystine
into the cell in exchange for glutamate. By releasing glutamate, system xc- can
potentially cause excitotoxicity. However, through providing cystine to the cell it
regulates the levels of cellular glutathione (GSH), the main endogenous intracellular
antioxidant, and may protect cells against oxidative stress. We tested two different
compounds that deplete primary cortical cultures containing both neurons and astrocytes
of intracellular GSH, L-buthionine-sulfoximine (BSO) and diethyl maleate (DEM). Both
compounds caused significant, concentration and time-dependent decreases in
intracellular GSH levels. However, DEM caused an increase in radiolabeled cystine
uptake through system xc-, while unexpectedly BSO caused a decrease in uptake. The
compounds caused similar low levels of neurotoxicity, while only BSO caused an
increase in oxidative stress. The mechanism of GSH depletion by these two compounds
is different, DEM directly conjugates to GSH, while BSO inhibits γ-glutamylcysteine
synthetase, a key enzyme in GSH synthesis. As would be expected from these
mechanisms of action, DEM caused a decrease in intracellular cysteine, while BSO
increased cysteine levels. The results suggest that negative feedback by intracellular
cysteine is a more important regulator of system xc- than intracellular GSH in this culture
system.
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Introduction
Under normal physiological conditions, the cystine/glutamate exchanger (system
xc-) mediates the transport of cystine into the cell in exchange for releasing glutamate
into the extrasynaptic space. The exchange of extracellular cystine and intracellular
glutamate occurs in a one to one ratio. The function of system xc- makes it likely to play
an important role in regulating neuronal survival and death. By releasing glutamate,
system xc- can increase extracellular glutamate levels and potentially cause
excitotoxicity. Release of glutamate via system xc-, from both microglia and astrocytes
has been shown to enhance excitotoxicity of cortical neurons. (Qin et al., 2006; Fogal et
al, 2007; Jackman et al, 2010; Liu et al., 2014) However, through providing cystine to the
cell, it regulates the levels of intracellular glutathione (GSH), the main endogenous
intracellular antioxidant, and in this way may protect cells against oxidative stress
(Murphy et al., 1989; Shih et al., 2006).
Not only does system xc- act to prevent oxidative stress, but it appears that such
stress is an important trigger for its upregulation. Direct induction of oxidative stress has
been shown to upregulate system xc- function in a retinal ganglion cell line (Dun et al.,
2006) and in retinal Muller glial cells (Mysona et al., 2009). Compounds that deplete
cellular GSH levels upregulate system xc- function in a glioma cell line (Kim et al., 2001)
and in primary astrocytes (Seib et al., 2011), although there is not always a correlation
between depletion of GSH and upregulation of system xc- (Sasaki et al., 2002).
The first step in the production of GSH in the brain is believed to involve uptake
of cystine, primarily into astrocytes (Kranich et al., 1998). Most of the cystine
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transported into cortical astrocytes appears to be through system xc- (Lobner, 2009).
Once in the astrocytes cystine is immediately broken down by thioredoxin reductase 1
into two cysteine molecules (Arrick et al., 1985). GSH is synthesized via a two-step
reaction (Beutler, 1989; Deneke and Fanburg, 1989). First, glutamate and cysteine are
catalyzed to γ-glutamylcysteine by γ-glutamylcysteine synthetase. Then glutathione
synthetase combines glycine with γ-glutamylcysteine forming GSH. Both glutamate and
glycine are highly available in the cells, so the rate-limiting factor in the production of
GSH is the levels of cysteine present in the cell (Dringen and Hirrlinger, 2003).
Glutathione can be utilized by cells to reduce reactive oxygen species; for
example, superoxide produced as a byproduct of mitochondrial energy production rapidly
reacts to form hydrogen peroxide which is then reduced by GSH to form glutathionedisulfide (GSSG) and water in a reaction catalyzed by glutathione peroxidase.
Glutathione may also be utilized as a xenobiotic detoxicant as has been well
characterized involving chemotherapeutics in cancer treatment (Salinas and Wong,
1999). That is, GSH can be directly conjugated to exogenous substrates via a disulfide
bond with the free sulfhydryl groups; these reactions are directed by a class of enzymes
known as glutathione-S-transferases (GSTs) (Dringen and Hirrlinger, 2003; Dringen,
2000). GSH, GSSG and the glutathione-conjugates are then exported from the cell in a
glutathione-dependent manner via multi-drug resistance proteins (MRP), specifically
MRP1 in the CNS (Hirrlinger and Dringen, 2005; Minich et al., 2006). GSH molecules
produced by astrocytes can then be broken down in the extracellular space by glutathione
reductase, amino-peptidase N, or γ-glutamyl transpeptidase. This metabolism produces
the substrate cysteine, which can be taken up and utilized by neurons to produce their
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own GSH (Fellin and Carmignoto, 2004; Stipursky et al., 2011; Yoshiba-Suzuki et al.,
2011). In this way, neurons are dependent on astrocytes to supply the substrate for their
GSH production (Dringen et al., 1999). The importance of cysteine uptake into neurons
is indicated by the finding that knocking out the excitatory amino acid transporter-3
(EAAT3) greatly reduces neuronal cysteine uptake and intracellular GSH levels, resulting
in decreased viability of hippocampal neurons against hydrogen peroxide insults (Chen
and Swanson, 2003; Aoyama et al., 2006).
The current studies used mixed cultures of neurons and astrocytes to be able to
incorporate the important interaction between these cell types. The studies involve
assessing the effects of two different approaches to depleting cellular GSH. Diethyl
maleate (DEM) directly conjugates to GSH while buthionine sulfoximine (BSO) inhibits
γ-glutamylcysteine synthetase preventing the production of GSH. The studies were
designed to determine the effects of these different mechanisms of GSH depletion on
system xc- function.
Materials and Methods
Materials
Timed pregnant Swiss Webster mice were obtained from Charles River
Laboratories (Wilmington, DE, USA). Serum was from Atlanta Biologicals (Atlanta,
GA, USA). NADPH was from Applichem (Darmstadt, Germany). Radiolabeled 14CCystine was purchased from PerkinElmer (Boston, MA, USA). DCF was from
Molecular Probes (Eugene, OR, USA). All other chemicals were from Sigma-Aldrich
(St. Louis, MO, USA).
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Cortical Cell Cultures
Mixed cortical cell cultures containing glial and neuronal cells were prepared
from fetal (15-16 day gestation) mice as previously described (Lobner, 2000).
Dissociated cortical cells were plated on 24-well plates (2.0 cm2 surface area per well)
coated with poly-D-lysine and laminin in Eagles’ Minimal Essential Medium (MEM,
Earle’s salts, supplied glutamine-free) supplemented with 5% (v/v) heat-inactivated horse
serum, 5% (v/v) fetal bovine serum, 2 mM glutamine and D-glucose (total 21 mM).
Cultures were maintained in humidified 5% CO2 incubators at 370C with experiments
performed on cultures DIV 13-15. Mice were handled in accordance with a protocol
approved by our institutional animal care committee and in compliance with the Public
Health Service Policy on Humane Care and Use of Laboratory Animals. All efforts were
made to minimize animal suffering and reduce the number of animals used. Experiments
were performed in media lacking serum (MS) but otherwise identical to the growth
media.
Assay of neuronal death
Cell death was assessed in cultures by the measurement of lactate dehydrogenase
(LDH), released from damaged or destroyed cells, in the extracellular fluid 24 hours after
the beginning of the insult. Control LDH levels were subtracted from insult LDH values,
and results normalized to 100% neuronal death caused by 500 µM NMDA. Control
experiments have shown previously that the efflux of LDH occurring from either necrotic
or apoptotic cells is proportional to the number of cells damaged or destroyed (Lobner,
2000; Koh and Choi, 1987). Cultures were also examined visually following trypan blue
staining.
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2’,7’-dichlorofluorescein (DCF) assay of oxidative stress
Oxidative stress was assayed by measuring DCF oxidation using a fluorescent
plate reader following a modification of a previous method (Wang and Joseph, 1999;
Lobner et al., 2007). Briefly, cultures were exposed to 100µM DEM or BSO for the
indicated period of time after which they were exposed to 5-(and –6)-carboxy-2’7’dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (10 mM). The carboxyH2DCFDA is de-esterfied within cells to form a free acid that can then be oxidized to the
fluorescent 2’7’-dichlorofluorescein (DCF). After a 30 minute exposure to carboxyH2DCFDA, cultures were washed 3 times with culture media lacking serum.
Fluorescence was then measured using a Fluoroskan Ascent fluorescence plate reader
(ThermoLabsystems). The excitation filter was set at 485 nm and emission filter at 538
nm. Background fluorescence (no carboxy-H2DCFDA added) was subtracted and the
results normalized to control conditions (carboxy-H2DCFDA added but no DEM or
BSO).
Monochlorobimane (MCB) assay of cellular reduced GSH
Cellular GSH levels were measured by MCB fluorescence. MCB forms a
fluorescent compound when it reacts with GSH through a reaction catalyzed by
glutathione-S-transferase (Pauly et al., 2011). Cultures were exposed to the indicated
concentrations of DEM or BSO for the indicated period of time after which they were
exposed to MCB (10 mM). After 30 minutes the cultures were excited at a wavelength of
355 nm and emission measured at a wavelength of 460 nm using a Thermo Labsystems
Fluoroskan microplate reader. Background (no MCB added) was subtracted and the
results normalized to control (MCB added but no DEM or BSO).
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HPLC analysis of cellular cysteine levels
To assess cysteine concentrations, cultures were exposed to MS containing the
indicated drug for 6 or 24 hours. After the indicated time, cultures were washed with
balanced salt solution (BSS) and then scraped into 250µL HPLC mobile phase. Cells
were collected into microcentrifuge tubes, sonicated using a probe sonicator and analyzed
for protein content using the common BCA method. Once the protein content was
determined, the homogenized samples were spun through a centrifugal filter and the
resulting protein free sample was injected onto a Shimadzu HPLC system coupled with
an electrochemical detector. Separation was obtained with a reverse phase C-18 column
and an ion-pairing mobile phase (50 mM citric acid, 10 mM octane sulfonic acid, pH
2.80, 1% acetonitrile). Resulting cysteine concentrations were normalized by the protein
content and values are reported as percent control.
14

C-Cystine Uptake
Radiolabeled cystine uptake was performed as previously described with

modifications (Liu et al., 2009). Cultures were exposed to MS containing the indicated
drug treatments for 40 min, 6 hrs, or 24 hrs. After the drug exposure cultures were
washed into HEPES buffered saline solution and immediately exposed to 14C-cystine
(0.025 µCi/mL, 200 nM total cystine) for 20 minutes. Following 14C-cystine exposure,
cultures were washed with ice cold HEPES buffered saline solution and dissolved in
250µl warm sodium dodecyl sulfate (0.1%). An aliquot (200µl) was removed and added
to scintillation fluid for counting. Values were normalized to control.
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Statistical Analysis
Differences between test groups were examined for statistical significance by
means of one-way ANOVA followed by the Bonferroni post-hoc analysis, with p<0.05
being considered significant.
Results
We set out to determine whether depleting cellular GSH alters system xc- activity
as assessed by measuring 14C-cystine uptake in mixed cortical cell cultures. We have
shown previously that the large majority of 14C-cystine uptake in mixed cortical cultures
is mediated by system xc- uptake into astrocytes (Lobner, 2009). In the current studies
cellular GSH levels were depleted using two compounds with different mechanisms of
action. DEM directly conjugates to GSH, while BSO inhibits GSH synthesis. Varying
concentrations of DEM were added to mixed cortical cultures for 40 min, 6 hr, or 24 hrs,
with 14C-cystine uptake measured for 20 minutes following the exposure. DEM caused a
significant increase in 14C-cystine uptake at all timepoints at a concentration of 100µM,
and at 6 and 24 hrs at the 10µM concentration (Figure 3.1). In contrast to DEM, when
cultures were exposed to BSO at the same concentrations it did not cause an increase in
14

C-cystine uptake at any concentration or timepoint. In fact, BSO at a concentration of

100µM caused a significant decrease in 14C-cystine uptake after 6 hr treatment, while
both 10 and 100µM BSO caused a decrease at 24 hrs (Figure 3.1).
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Figure 3.1 Diethyl maleate (DEM) exposure causes an increase, while buthionine
sulfoximine (BSO) exposure causes a decrease, in 14C-cystine uptake in mixed cortical
cultures. Cultures were exposed to varying concentrations of DEM or BSO for A) 40
min, B) 6 hrs, or C) 24 hrs, after thorough washing, 14C-cystine uptake was measured for
20 minutes. Results are expressed as mean ± s.e.m (n=8-16) after normalizing to
untreated control uptake. * indicates significant difference from DEM control; # indicates
significant difference from BSO control, one-way ANOVA (p < 0.05).
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To test whether the increased uptake induced by DEM treatment was mediated by
system xc-, the inhibitor of that system, sulfasalazine (SSZ), was added during the uptake
period following exposure to 100µM DEM. The SSZ treatment completely blocked the
increased 14C-cystine uptake induced by DEM (Figure 3.2).

Figure 3.2 DEM induced increase in 14C-cystine uptake is mediated by system xc-.
Cultures were exposed to 100µM DEM for 40 min, 6 hrs, or 24 hrs, after thorough
washing, 14C-cystine uptake was measured for 20 minutes with or without the system xcinhibitor sulfasalazine (SSZ) present. Results are expressed as mean ± s.e.m (n=8-16)
after normalizing to untreated control uptake. * indicates significant difference from 40
min control; # indicates significant difference from 6 hour control; @ indicates
significant difference from 24 hour control, one-way ANOVA (p < 0.05).
A potential cause for altered 14C-cystine uptake could be toxicity of DEM or
BSO. DEM and BSO both caused a small, but significant level of neurotoxicity after 24
hours at the 100µM concentrations (Figure 3.3). Trypan blue staining indicated that the
death was selective for neurons (data not shown).

82

Figure 3.3 DEM and BSO cause similar low levels of neurotoxicity. Concentration
response curve for 24-hour exposure to DEM and BSO on LDH release in primary
cortical cultures. Results are expressed as mean ± s.e.m (n=8-16). * indicates significant
difference from untreated control, one-way ANOVA (p < 0.05).
A potential mechanism by which DEM may have caused increased system xcactivity is through inducing oxidative stress, which has been shown to upregulate system
xc- (Dun et al., 2006; Mysona et al., 2009). We measured cellular oxidative stress with
the compound DCF, which becomes fluorescent when oxidized. Somewhat surprisingly
we did not see enhanced DCF fluorescence following 100µM DEM treatment, while
100µM BSO only caused an increase following 24 hr treatment (Figure 3.4).
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Figure 3.4 BSO, but not DEM, causes an increase in cellular oxidative stress after a 24hour treatment. Bars show % DCF fluorescence normalized to control fluorescence
(mean ± s.e.m, n=8-16). * indicates significant difference from control, one-way
ANOVA (p < 0.05).
Another potential mechanism by which DEM may be causing increased system
xc- function is through causing decreased GSH levels. DEM and BSO treatment both
caused a decrease in cellular GSH levels (Figure 3.5). There were some differences in
the decrease; DEM caused a more rapid decrease in GSH, with a significant decrease at
the 40 minute timepoint, while BSO did not cause a significant decrease until the 6 hr
timepoint. The GSH levels with DEM treatment actually increased from the 6 hr
timepoint to the 24 hr timepoint, so that at 24 hrs, BSO caused a greater decrease in GSH
levels than DEM.

84

Figure 3.5 DEM and BSO cause a concentration dependent decrease in cellular
glutathione levels. Cultures were exposed to varying concentrations of DEM or BSO for
A) 40 min, B) 6 hrs, or C) 24 hrs, after which cellular reduced glutathione was
determined by MCB fluorescence. Bars show % MCB fluorescence normalized to
control fluorescence (mean ± s.e.m, n=8-16). * indicates significant difference from
DEM control; # indicates significant difference from BSO control, one-way ANOVA (p
< 0.05).

85
While DEM and BSO both act to decrease GSH levels they do so by different
mechanisms suggesting the possibility that they may alter cellular cysteine levels
differently. We found that 100µM DEM caused a significant decrease in cellular cysteine
levels after 6 hr treatment with the effect disappearing at 24 hours, while 100µM BSO
caused a significant increase in cellular cysteine after 6 and 24 hr treatment (Figure 3.6).

Figure 3.6 DEM causes an early decrease in cellular cysteine levels, while BSO causes
an early and late increase in cellular cysteine levels. Cultures were exposed to varying
concentrations of DEM or BSO for A) 6 hrs or B) 24 hrs, after which cellular cysteine
levels were determined by HPLC. Bars show % cellular cysteine normalized to control
(mean ± s.e.m, n=8). * indicates significant difference from DEM control; # indicates
significant difference from BSO control, one-way ANOVA (p < 0.05).
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Discussion
The regulation of system xc- function is proving to be complicated, likely because
of its varied functions. Upregulation of system xc- by oxidative stress has been well
established and this regulation is mechanistically understandable considering that system
xc- is important for cystine uptake and therefore GSH production. However, system xcfunction has also been shown to be upregulated by a diverse array of compounds
including IL-1b (Fogal et al., 2007), erythropoietin (Sims et al., 2010), FGF-2 (Liu et al.,
2012), IGF-1 (Pauly et al., 2011; Yang and Yee, 2014), TGF-b (Pauly et al., 2011), and
PACAP (Resch et al., 2014). While system xc- function has been shown to be decreased
by dexamethasone (Piani and Fontana, 1994), regulation by these diverse compounds
may reflect the importance of system xc- in regulating not only oxidative stress but also
extracellular glutamate. For example, it has been shown that cocaine addiction is
associated with impaired system xc- function leading to decreased activation of
presynaptic group II mGluRs leading to increased synaptic release of glutamate (Baker et
al., 2002; Baker et al., 2003). It is likely that the regulation of system xc- by these
compounds reflects the importance of regulating both intracellular GSH and extracellular
glutamate. Another factor to consider is that there is an interaction between system xcand excitatory amino acid transporters (EAATs) (Lewerenz et al., 2009). The possibility
that altered EAAT function could change glutamate concentrations and in this way
change system xc- function exists.
The goal of the current study was to examine in more detail the regulation of
system xc- by agents that deplete GSH. The previous thinking about such agents is that
they upregulated system xc- by depletion of cellular GSH, and either this depletion
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directly stimulated system xc-, or the resulting increased oxidative stress caused the
upregulation. Our results indicate another potential mechanism of regulation. In our
studies, simple depletion of cellular GSH did not appear to be the trigger for upregulation
of system xc-. While there were some differences in the time course and concentration
dependence of the effects of DEM and BSO treatment on GSH levels, they both caused
depletion of GSH and yet they had opposite effects on system xc- function. These results
are difficult to explain by the different time courses in effects on GSH levels. If BSO
caused no effect on system xc- function this could potentially be explained by its slower
depletion of GSH, but the fact that it actually caused a decrease in system xc- activity
seems unlikely to be explained by the slower loss of GSH with BSO treatment than with
DEM treatment. Interestingly, the GSH levels following DEM treatment actually
increased from the 6 hr timepoint to the 24 hr timepoint (Figure 3.5). This increase is
likely due to the upregulation of system xc- under these conditions leading to increased
cystine uptake and additional substrate for GSH production.
Toxicity due to treatment with DEM or BSO could be a potential confound when
assessing cystine uptake. However, both compounds caused only a small degree of
neurotoxicity (10-15%) after 24 hours. This toxicity seems unlikely to play a major role
in the results for three reasons. First, DEM and BSO caused similar toxicity but had
opposite effects on cystine uptake. Second, the levels of cell death were small compared
to the magnitude of changes in cystine uptake. Third, the cell death was selective for
neurons, while most the cystine uptake in this culture system is into astrocytes (Lobner,
2009).

88
The result that DEM did not induce oxidative stress, as measured by DCF
fluorescence, suggests that increased oxidative stress is not the mechanism by which
DEM upregulates system xc- function, particularly since BSO did induce oxidative stress
while it actually decreased system xc- function. However, it was somewhat surprising
that DEM did not induce oxidative stress since it did decrease the levels of GSH. There
are a number of possible explanations for this result. First, GSH is not the only
antioxidant present in the brain. Under the conditions we were studying it is possible that
decreased GSH levels would not lead to enhanced oxidative stress in the cells. Second,
the DCF assay does not detect all forms of free radicals (Gomes et al., 2005) and it may
be less effective in detecting mitochondria selective oxidative stress (Karlsson et al.,
2010). Therefore while we cannot absolutely conclude that oxidative stress is not the
trigger for upregulation of system xc- by DEM, the fact that BSO caused a marked
increase in oxidative stress while DEM did not, and yet BSO caused a decrease in system
xc- function, suggests that factors other than oxidative stress are more important in
regulation of system xc- in this system.
Our results suggest that, at least for our cell culture system, cysteine is a more
important regulator of system xc- function than GSH. DEM caused both a decrease in
cysteine and GSH levels, consistent with its action to conjugate GSH leading to constant
use of cellular cysteine. Therefore, either the decrease in cysteine or GSH could be
responsible for the upregulation of system xc-. However, BSO also decreased GSH, but
increased cysteine levels, consistent with its action to inhibit γ-glutamylcysteine
synthetase leading to GSH depletion but buildup of cysteine, and it caused a
downregulation of system xc- function. In this case, the most likely explanation for the
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effect is that the buildup of cysteine provides negative feedback on system xc- function.
This type of regulation makes sense physiologically. The levels of cysteine in the cell are
more directly related to the uptake of cystine than they are to the levels of GSH.
Glutathione levels in cells could be altered by changes in the function of γglutamylcysteine synthetase or glutathione synthetase, or potentially the availability of
glycine or glutamate. Therefore, if system xc- was upregulated by GSH depletion it could
be in response to conditions unrelated to the availability of cystine. Additionally,
cysteine levels in the brain are 100 times lower than GSH levels (Slivka and Cohen,
1993) and therefore, rapid changes in their levels are more likely to occur than changes in
GSH levels.
Our results are in contrast to those of Seib et al. (2011), who found a large
increase in system xc- function in astrocytes after treatment with BSO. There are two
major differences in the culture systems used for the studies. First, we used a mixed
neuronal and astrocyte culture, while in the Seib et al. study they used a pure astrocyte
culture. The possibility exists that the interaction of neurons with the astrocytes alters the
how-cells-regulate system xc-. Second, their cultures received long-term treatment with a
cell permeant form of cAMP prior to the BSO treatment. From their studies, it is clear
that GSH levels can also be an important regulator of system xc-, but that the status of the
cells likely determines the relative importance of cysteine or GSH in the regulation. We
cannot exclude the possibility that GSH plays a role in regulating system xc- even in our
culture conditions, but it appears that cysteine levels have a greater effect than GSH on
system xc- function. The implications this finding has for the role of system xc- in
disease conditions is not certain. Cysteine levels are not as commonly measured as GSH
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levels. For example, we have found that system xc- function is increased at 70 days of
age in the G93A-SOD1 mouse model of ALS (Albano et al., 2013), a timepoint at which
GSH levels are not yet decreased (Chi et al., 2007), but intracellular cysteine levels are
unknown.
In conclusion, our studies indicate that, at least under some conditions,
intracellular levels of cysteine are a more important regulator of system xc- than
intracellular levels of GSH. We did not determine the mechanism of regulation by
cysteine, but the redox sensitive transcription factor Nrf2 has been shown to be the main
regulator of system xc- (Sasaki et al., 2002; Shih et al., 2003). This finding puts system
xc- in the context of it being one factor in the role of Nrf2 as the master regulator of the
cellular response to oxidative stress (Ishii and Mann, 2014). In conclusion, studies
involving assessment of levels of cysteine, GSH, and system xc- function during disease
conditions will be required to determine the most important regulator of system xcfunction in disease states.
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CHAPTER IV
TGF-β1 INDUCED UPREGULATION OF SYSTEM XC- IN ASTROCYTES
ENHANCES NEURONAL DEATH
Abstract
System xc-, the cystine/glutamate exchanger, mediates the transport of one cystine
molecule into the cell in exchange for the release of one glutamate molecule into the
extrasynaptic space. Cystine transported into the cell is converted to glutathione (GSH),
the main antioxidant in the brain, which protects the cell from oxidative stress. However,
the release of glutamate into the extrasynaptic space can lead to excitotoxicity.
Transforming growth factor-β1 (TGF-β1) is a cytokine involved in regulating many
cellular processes, including neuronal survival and death. In this study we determined
whether TGF-β1 regulates system xc- function and if system xc- plays a role in the effects
of TGF-β1 activity on neuronal survival/death. We found that TGF-β1 increased 14Ccystine uptake through system xc- in astrocyte-enriched glial cultures, which required
both TGF-β1 receptors ALK5 and ALK1 and was mediated through the MAPK/ERK
pathway. TGF-β1 increased xCT mRNA levels and the increased uptake was blocked by
the protein synthesis inhibitor cycloheximide. Interestingly, TGF-β1 increased the export
of GSH from astrocytes to be utilized by neurons, which would suggest a neuroprotective
role for TGF-β1. However, in mixed cortical cultures TGF-β1 enhanced rotenoneinduced toxicity, an effect mediated through AMPA receptors. Together the data
suggests that the increase in system xc- activity by TGF-β1 may have antioxidant
defenses, but can also exacerbate excitotoxicity.
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Introduction
Transforming growth factor-β1 (TGF-β1) is a cytokine with wide ranging effects
in the CNS, including regulating cellular processes like growth and development (Böttner
et al., 2000; Massagué et al., 2000), differentiation (Ishihara et al., 1994), and apoptosis
(Prehn et al., 1994; Zhu et al., 2001; 2002). TGF-β1 is one of three TGF-β isoforms and
is part the TGF-β superfamily, which includes multiple cytokines. While its receptors,
TGF-β receptor I and II (TGF-βRI, -II), are found throughout the brain and are expressed
on neurons, astrocytes, and microglia (Böttner et al., 1996; Vivien et al., 1998; Vivien
and Ali, 2006), TGF-β1 expression is very low during development and in the adult brain
(Flanders et al., 1991; Pelton et al., 1991; Unsicker et al., 1991). While some studies
show it is mainly confined to the meninges and choroid plexus (Unsicker et al., 1991),
others have found it is present in the cerebral cortex (Vivien et al., 1998). However, in
response to injury and neurodegeneration TGF-β1 is highly upregulated and secreted by
many different cell types (Pratt and McPherson, 1997; Flanders et al., 1998; Vivien and
Ali, 2006), which makes its potential role in neuronal protection and death of interest.
TGF-β1 has been well studied in models of focal and global ischemia, where it is
upregulated in the infarct and penumbral areas (Krupinski et al., 1996) and has protective
effects (Prehn et al., 1993; Henrich-Noack et al., 1996; Pang et al., 2001). It is also
protective against β-amyloid toxicity (Prehn et al., 1996; Ren and Flanders, 1996), MPP+
toxicity to dopaminergic neurons (Krieglstein et al., 1995), apoptosis (Prehn et al., 1994;
Zhu et al., 2001; 2002) and oxidative stress mediated neuronal death (Henrich-Noack et
al., 1996). Interestingly, while TGF-β1 has been shown to be neuroprotective in acute
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excitotoxicity models, in chronic excitotoxicity models TGF-β1 enhances toxicity (Prehn
and Kriedglstein, 1994; Prehn and Miller, 1996).
The cystine/glutamate antiporter (system xc-) is a sodium-independent amino acid
transporter found on astrocytes, which takes up one molecule of cystine into the cell in
exchange for one molecule of glutamate (Bannai and Kitamura, 1980; Bannai, 1986).
The cystine that is imported is quickly reduced to cysteine and used to synthesize
glutathione (GSH) (Bannai and Kitamura, 1980). GSH is the main endogenous
antioxidant in the brain and protects against oxidative stress; it can be released by
astrocytes and used to protect neurons (Shih et al., 2003). Cysteine can also be released
by astrocytes and taken up by surrounding neurons to synthesize GSH (Lewerenz et al.,
2006; Wang and Cynader, 2000). In exchange for taking up one molecule of cystine,
system xc- releases one molecule of glutamate into the extrasynaptic space and is the
major source of extracellular glutamate in several rodent brain regions (De Bundel et al.,
2011; Massie et al., 2011; Baker et al. 2002). The glutamate released by system xc- can
activate extrasynaptic receptors and regulate synaptic function (Baker et al., 2002;
Williams and Featherstone, 2014). However, high extracellular levels of glutamate
released via system xc- can also lead to excitotoxicity (Fogal et al., 2007; Hardingham
and Bading, 2010; Liu et al., 2014). The dual function of system xc- makes it likely to
play an important role in regulating neuronal survival and death.
Both TGF-β1 and system xc- are known to play a role in oxidative stress and
excitotoxicity, key players in many neurodegenerative diseases. TGF-β1 and system xcare also upregulated in neurodegenerative diseases (Flanders et al., 1998; Vivien and Ali,
2006; Massie et al., 2015). It is our hypothesis that TGF-β1 upregulates system xc- on
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astrocytes and some of the actions of TGF-β1 may be due its effects on system xc-. In
this present study we used primary astrocyte-enriched glial cortical cultures to study the
effects of TGF-β1 on system xc- and then used primary mixed cortical cultures to
investigate TGF-β1’s effect on neuronal survival/death in concert with an increase in
oxidative stress, a hallmark of many neurodegenerative diseases.
Materials and Methods
Materials
Timed pregnant Swiss Webster mice were obtained from Charles River
Laboratories (Wilmington, DE). Serum was from Atlanta Biologicals (Lawrenceville,
GA). TGF-β1 was from Prospec (East Brunswick, NJ) and 14C-cystine was from
PerkinElmer (Waltham, MA). TRIzol was obtained from Life Technologies (Grand
Island, NY). The reverse transcription kit was from Promega (Madison, WI) and the
PerfeCTa SYBR Green FastMix with ROX from Quanta Biosciences (Gaithersburg,
MD). Primers were obtained from Integrated DNA Technologies (Coralvilla, IA). All
other chemicals were obtained from Sigma (St. Louis, MO).
Cortical cell cultures
Mixed cortical cell cultures containing glial and neuronal cells were prepared
from fetal (15-16 day gestation) mice as previously described (Lobner, 2000).
Dissociated cortical cells were plated on 24-well plates coated with poly-D-lysine and
laminin in Eagles’ Minimal Essential Medium (MEM, Earle’s salts, supplied glutaminefree) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine serum, 2mM
glutamine and glucose (total 21 mM). Neuron-enriched cultures were prepared exactly as
above with the addition of 10µM cytosine arabinoside 48 hours after plating to inhibit

95
glial replication. In these cultures <1% of cells are astrocytes (Dugan et al., 1995; Rush
et al., 2010). Astrocyte-enriched glial cultures were prepared as described for mixed
cultures except they are from cortical tissue taken from post-natal day 1-3 mice (Choi et
al., 1987; Schwarts and Wilson, 1992; Rush et al., 2010). Pure astrocyte cultures were
prepared from astrocyte-enriched glial cultures as described by Hamby et al. (2006).
Microglia cultures were prepared by first growing astrocyte enriched glial cultures, then
shaking the microglia free and plating them in media containing 10 ng/ml colony
stimulating factor (CSF) (Barger and Basile, 2001). Cultures were maintained in
humidified 5% CO2 incubators at 37°C. Mice were handled in accordance with a
protocol approved by our institutional animal care committee and in compliance with the
Public Health Service Policy on Humane Care and Use of Laboratory Animals. All
efforts were made to minimize animal suffering and reduce the number of animals used.
14

C-Cystine Uptake
System xc- mediated uptake of radiolabeled cystine was assayed as previously

described with modifications (Liu et al., 2009). Astrocyte-enriched glial cultures were
exposed to media lacking serum (MS) containing 100ng/mL TGF-β1 for the indicated
time in humidified 5% CO2 incubators at 37°C. In experiments where inhibitors were
used, the inhibitors were added 1 hour prior to the addition of TGF-β1 and remained in
the media for the duration of the incubation time. After the indicated time, cultures were
washed with HEPES buffered saline solution and immediately exposed to 14C-cystine
(0.025µCi/mL) for 20 minutes. In experiments where 14C-cystine uptake through system
xc- was blocked, 300µM sulfasalazine (SSZ) was added just prior to radiolabeled cystine.
Following 14C-cystine exposure, all cultures were washed with HEPES buffered saline
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solution and dissolved in 250µL warm sodium dodecyl sulfate (0.5%). A 200µL aliquot
was removed and added to scintillation fluid for counting. Values were normalized to
14

C-cystine uptake in untreated controls on the same experimental plate.

Assay of neuronal death
Mixed and astrocyte-enriched glial cultures were washed with MS containing
100ng/mL TGF-β1 for 24 hours. 100nM rotenone was then added, either with or without
the other inhibitors indicated for another 24 hours. Cell death was assessed in mixed and
astrocyte-enriched glial cultures by the measurement of lactate dehydrogenase (LDH)
released from damaged or destroyed cells, in the extracellular fluid 48 hours after the
beginning of the insult. Control LDH levels were subtracted from insult LDH values and
results normalized to 100% neuronal death caused by 500 µM NMDA for mixed cultures
or 100% astrocyte death caused by 20µM of the calcium ionophore A23187, added 24
hours before the assay. Control experiments have shown previously that the efflux of
LDH occurring from either necrotic or apoptotic cells is proportional to the number of
cells damaged or destroyed (Koh and Choi, 1987; Lobner, 2000).
Monochlorobimane (MCB) assay of cellular reduced GSH
Cellular GSH levels were measured by MCB fluorescence. MCB forms a
fluorescent compound when it reacts with GSH through a reaction catalyzed by
glutathione-S-transferase (Pauly et al., 2011). Astrocyte-enriched glial cultures were
exposed to MS containing 100ng/mL TGF-β1 for 24 hours. MCB (final concentration of
10µM) was added to each sample 30 minutes prior to the end time. A 200µL sample was
taken from the media. The cells were then washed three times with cold HBBSS and
dissolved with 250µL DMSO. A 200µL sample was placed into a 96-well plate.
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Samples were read at 355/460 with a Fluoroskan Ascent Microplate Fluorometer
(Thermo LabSystems). Results were normalized to control conditions.
Reverse transcription quantitative real-time PCR (RT-qPCR)
Transcriptional expression of xCT in astrocyte-enriched glial cultures after
stimulation with TGF-β1 was examined using RT-qPCR. Briefly, after treating cells with
TGF-β1 for various time points, cells were washed 3 times with cold PBS. Total RNA
was isolated with TRIzol extraction (Invitrogen; Carlsbad, CA) according to
manufacturer’s protocol. RNA quality was determined using spectrophotometry with a
260/280 ratio of >1.8. cDNA was synthesized using the Reverse Transcription System
(Promega; Madison, WI) from 1 mg of total RNA following the manufacturer’s protocol.
All products were amplified on a StepOne real-time PCR system (Applied Biosystems;
Carlsbad, CA) using 100 ng of cDNA, PerfeCTa SYBR Green FastMix with ROX
(Quanta Biosciences; Gaithersburg, MD), and the following primers designed using
Primer3 software: gapdh mouse forward-AAG GGC TCA TGA CCA CAG TC; gapdh
mouse reverse-GGA TAC AGG GAT GAT GTT CT; xCT mouse forward- TCA CTT
TTT GGA GCC CTG TC; xCT mouse reverse- ACC CAG ACT CGA ACA AAA GC.
Relative quantification of xCT transcripts was analyzed via the 2-∆∆Ct method normalized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Statistical analysis
Differences between test groups were examined for statistical significance by
means of t-test or one-way ANOVA followed by the Bonferroni correction post-hoc test,
with p<0.05 being considered significant.
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Results
We first tested the effects of TGF-β1 on 14C-cystine uptake in purified cultures of
astrocytes, microglia, and neurons. A 24-hour treatment with TGF-β1 caused a
significant increase in 14C-cystine uptake in pure astrocyte cultures, but not in microglia
or pure neuronal cell cultures (Figure 4.1). The following experiments, unless otherwise
noted, were performed in astrocyte-enriched glial cultures. We next tested if the TGF-β1
induced increase in 14C-cystine uptake was mediated by system xc-; addition of the
system xc- inhibitor, sulfasalazine (SSZ), blocked the TGF-β1 induced increase in 14Ccystine uptake (Figure 4.2).

A

C

Pure Astrocyte Culture

Neuronal Enriched Culture

B

Microglial Culture

Figure 4.1 Transforming growth factor β1
(TGF-β1) causes an increase in 14C-cystine
uptake in A) pure astrocyte cultures, but not
in B) microglial cultures or C) neuronal
enriched cultures. Cultures were exposed
to TGF-β1 (100ng/mL) for 24 hours. TGFβ1 was washed out and 14C-cystine uptake
was measured for 20 minutes. Results are
expressed as mean ± s.e.m (n=8-16) after
normalizing to untreated control uptake.
* indicates significant difference from
control, t-test (p < 0.05).
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Figure 4.2 TGF-β1 increases 14C-cystine uptake through system xc-. Astrocyte
enriched cultures were exposed to TGF-β1 (100ng/mL) for 24 hours and after
thorough washing, 14C-cystine uptake was measured for 20 minutes with or
without the system xc- inhibitor sulfasalazine (SSZ, 300mM) present. Results are
expressed as mean ± s.e.m (n=8-16) after normalizing to untreated control uptake.
* indicates significant difference from control; # indicates significant difference
from TGF-β1 alone, one-way ANOVA (p < 0.05).
The increased system xc- mediated 14C-cystine uptake could be mediated by
alteration of function of already present system xc- or increased system xc- protein. To
assess this, we first performed a time course of TGF-β1’s effects on 14C-cystine uptake.
TGF-β1 caused no increase in 14C-cystine uptake with treatment up to 12 hours (Figure
3A). The long duration exposure for increased uptake suggests new protein synthesis is
required. To test this we added the protein synthesis inhibitor cycloheximide (CHX),
which completely blocked the TGF-β1 induced increase, during a 24-hour treatment
(Figure 3B). Since there are questions regarding antibody reliability (Massie et al., 2015)
we did not perform western blotting for the functional subunit of system xc-, xCT.
However, we performed qPCR and found that 24-hour application of TGF-β1 increased
xCT mRNA levels (Figure 3C).
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Figure 4.3 TGF-β1 induces a time
and protein synthesis dependent
increase in 14C-cystine uptake and
increases xCT mRNA expression. A)
TGF-β1 (100ng/mL) was applied for
various times to astrocyte-enriched
cultures. Cultures were then washed
and a 20 min 14C-cystine uptake assay
was performed. B) Cultures were
exposed to TGF-β1 with or without
the protein synthesis inhibitor
cycloheximide (CHX, 200ng/mL) for
24 hours and after thorough washing,
14
C-cystine uptake was measured for
20 minutes. Results are expressed as
mean±SEM (n=8-16) after
normalizing to untreated control
uptake. C) Astrocyte-enriched
cultures were exposed to TGF-β1 for
the duration indicated. RNA was
extracted using TRIzol and RT-PCR
was used to determine mRNA
expression. Results were normalized
to controls (set to 1) and presented as
mean ± s.e.m (n=4-5). * indicates
significant difference from control; #
indicates significant difference from
TGF-β1 alone, one-way ANOVA (p
< 0.05).
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TGF-β1 acts by binding to TGF-β receptor II (TGF-βRII), which then recruits and
phosphorylates a second receptor, TGF-βRI. There are two TGF-βRI isoforms that TGFβ1 signals through: activin receptor-like kinase 5 (ALK5) and ALK1 (Massagué, 1998).
We tested the ALK 5 inhibitor LY364947 and the ALK1 inhibitor K02288. Each of the
inhibitors caused a partial decrease in the TGF-β1 enhancement of 14C-cystine uptake,
with application of both inhibitors causing a near complete inhibition (Figure 4.4A).
TGF-β1 activates multiple intracellular pathways (Massagué, 2000). We tested the role
of the MEK/ERK pathway in the upregulation of system xc-. We found that the
MEK/ERK pathway inhibitor U0126 largely blocked the effect of TGF-β1 (Figure 4.4B).

A

B

Figure 4.4 TGF-β1 induced increase in 14C-cystine uptake is mediated by
activation of both ALK5 and ALK1 and the MAPK/ERK pathway. A) Astrocyteenriched cultures were treated with the ALK5 inhibitor LY364947 (LY, 10µM)
and/or the ALK1 inhibitor K02288 (K, 10µM) for 1 hour prior to and during
TGF-β1 (100ng/mL) exposure for 24 hours. After a thorough washing, 14Ccystine uptake was measured for 20 minutes. B) Cultures were exposed to the
MAPK/ERK pathway inhibitor U0126 (10µM) 1 hour prior and during exposure
to TGF-β1 for 24 hours and after thorough washing, 14C-cystine uptake was
measured for 20 minutes. Results are expressed as mean ± s.e.m (n=8-16) after
normalizing to untreated control uptake. * indicates significant difference from
control; # indicates significant difference from TGF-β1 alone, one-way ANOVA
(p < 0.05).
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The increase in cystine uptake would be expected to cause an increase in
intracellular GSH. However, in astrocyte-enriched cultures 24-hour treatment with TGFβ1 actually caused a decrease in cellular GSH (Figure 4.5A). There was also a small
decrease in pure neuronal cultures, but no effect in mixed cultures (Figure 4.5A). Testing
the levels of GSH in the media, we found an increase in the media from astrocyte
cultures, and small decrease in pure neuronal and mixed cultures (Figure 4.5B). The
results suggest that TGF-β1 may be stimulating the astrocytes to release glutathione,
which in turn supplies substrate for glutathione production in neurons. To test this
neurons were grown on culture inserts in the presence of astrocytes; after TGF-β1
treatment cultures were separated in order to test GSH levels in each cell type
individually. TGF-β1 treatment caused a decrease in cellular GSH in the astrocytes, but
no change in neurons (Figure 4.6).
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Figure 4.5 TGF-β1 decreases intracellular GSH levels in astrocyte-enriched (glia)
and neuronal-enriched (PNC) cultures, but not in mixed cultures; TGF-β1
increases extracellular GSH levels in astrocyte-enriched cultures. TGF-β1
(100ng/mL) was applied to the indicated culture system for 24 hours. 30 minutes
prior to the end time 1mM MCB was applied. Both the A) intracellular and B)
extracellular GSH levels were measured. Results are expressed as mean ± s.e.m
(n=8-16) after normalizing to untreated control. * indicates significant difference
from control, t-test (p < 0.05).

Insert System

Figure 4.6 In an insert system, TGF-β1 decreases intracellular GSH levels in
astrocyte-enriched (glia) cultures, but not in neuronal-enriched (PNC) cultures.
TGF-β1 (100ng/mL) was applied for 24 hours to astrocytes and neurons that had
been cultured together using an insert system. 30 minutes prior to the end time
1mM MCB was applied. The astrocytes and neurons were then separated so
intracellular GSH levels could be measured in each cell type separately. Results
are expressed as mean ± s.e.m (n=8-16) after normalizing to untreated control.
* indicates significant difference from control, t-test (p < 0.05).
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Upregulation of system xc- can have complicated effects on cell death due to its
dual role of providing cystine for GSH production, but also releasing glutamate, which
can cause excitotoxicity. We found that treatment of mixed cultures with TGF-β1 for up
to 48 hours did not cause any cell death (Figure 4.7). However, when cultures were
treated with TGF-β1 for 24 hours prior to and during 24-hour exposure to the
mitochondrial inhibitor rotenone (100nM) the TGF-β1 treatment enhanced the toxicity of
rotenone (Figure 4.7). The neuronal death induced by exposure to TGF-β1 and rotenone
was attenuated by treatment with the AMPA/kainate receptor antagonist, NBQX, (Figure
4.8A) but not by the NMDA antagonist, memantine (MEM), (Fig 4.8B) or the calcium
permeable AMPA receptor antagonist NASPM (Figure 4.8C). The toxicity was purely
neuronal, as the same treatment did not cause LDH release in astrocyte cultures (Figure
4.9). However, TGF-β1 did enhance rotenone-induced astrocyte toxicity when higher
levels of rotenone were applied (Figure 4.9).
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Figure 4.7 TGF-β1 enhances rotenone-induced toxicity in neurons. TGF-β1
(100ng/mL) was applied for 48 hours to mixed cortical cultures. 24 hours after
TGF-β1 application, 100nM rotenone was applied. Bars show % death (mean ±
s.e.m, n=8-16) quantified by measuring LDH release, 48 hours after the beginning
of the treatment with TGF-β1. * indicates significant difference from control; #
indicates significant difference from 100nM rotenone alone, one-way ANOVA (p
< 0.05).
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Figure 4.8 AMPA receptor
antagonist, NBQX, blocks
TGF-β1 enhanced rotenonetoxicity; NMDA receptor
antagonist, MEM, and Ca2+permeable AMPA receptor
antagonist, NASPM, do not.
TGF-β1 (100ng/mL) was
applied for 48 hours to mixed
cortical cultures. 24 hours
after TGF-β1 application,
rotenone (100nM) and A)
NBQX (7.5µM), B) MEM
(10µM), or C) NASPM
(10µM) were applied. Bars
show % neuronal death (mean
± s.e.m, n=8-16) quantified by
measuring LDH release, 48
hours after the beginning of
the treatment with TGF-β1. *
indicates significant
difference from control; #
indicates significant
difference from 100nM
rotenone alone, one-way
ANOVA (p < 0.05).
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Figure 4.9 TGF-β1 enhances rotenone-induced toxicity in astrocytes. TGF-β1
(100ng/mL) was applied for 48 hours to astrocyte-enriched cultures. 24 hours
after TGF-β1 application, the indicated amount of rotenone was applied. Bars
show % death (mean ± s.e.m, n=8-16) quantified by measuring LDH release, 48
hours after the beginning of the treatment with TGF-β1. * indicates significant
difference from control; # indicates significant difference from TGF-β1 alone,
one-way ANOVA (p < 0.05).
Discussion
TGF-β1 is known to have many diverse effects on the central nervous system
(Flanders et al., 1998) and this current study adds a novel effect of TGF-β1 to the
literature. Our results show that 24-hour application of TGF-β1 increased cystine uptake
through system xc- on astrocytes. The timecourse of system xc- upregulation by TGF-β1
suggests that new protein is being made; in support of this hypothesis, the protein
synthesis inhibitor, cycloheximide, blocked the TGF-β1 mediated increase in system xcfunction. Also, TGF-β1 increased xCT mRNA levels in a time dependent manner.
Together these data suggest that cystine uptake is increased through system xc- due to
increased system xc- expression.
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TGF-β1 can signal through multiple pathways and involves two receptors, TGFβRI and TGF-βRII. Both receptors I and II are serine/threonine kinases and TGF-βRI has
multiple isoforms. TGF-β1 signaling begins when TGF-β1 binds to TGF-βRII, which
recruits and phosphorylates TGF-βRI. TGF-βRI then initiates the intracellular signaling
cascade (Massagué, 1998). Interestingly, in this study the TGF-β1 induced increase in
system xc- activity requires both TGF-βRI isoforms, ALK1 and ALK5. Inhibiting one
receptor only partially blocked the increase in cystine uptake, while blocking both
receptors completely blocked the increase. Activation of both ALK1 and ALK 5
signaling has been observed previously, and certain biological responses have been
shown to be dependent upon recruitment of both isoforms (Goumans et al., 2003; König
et al., 2005).
Following TGF-βRI activation, TGF-βRI phosphorylates and activates signaling
mother against decapentaplegic (SMAD) proteins. SMAD proteins are transcription
factors and are the main signal transducers of TGF-β receptor activation (Massagué,
2000). More recently, however, other signaling pathways of TGF-βRI/II activation are
beginning to emerge (Massagué, 2000; Vivien and Ali, 2006). Along with being
serine/threonine kinases, recently it was discovered that TGF-βRI/II can also
phosphorylate tyrosine, which plays a role in activating the MAPK/ERK signaling
pathway (Lee et al., 2007; Zhang, 2009). In this study when added one hour prior to
TGF-β1, U0126 blocked the increase in system xc- activity, showing that the
MAPK/ERK signaling pathway was necessary for the increase system xc- activity. We
did not test inhibitors of other known TGF-β1 signaling pathways and therefore cannot
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rule out the involvement of these other pathways in TGF-β1’s affects on system xcactivity.
Given the function of system xc-, one would hypothesize that increased system xcactivity would also lead to increased intracellular GSH levels. However, our data
indicate the situation is complicated. Increased system xc- activity on astrocytes actually
led to decreased GSH levels in astrocytes. This appears to be due to TGF-β1 treatment
not only increasing cystine uptake into astrocytes, but also stimulating astrocytes to
release more GSH. When TGF-β1 was applied to pure neuronal cultures there was a
decrease in both intracellular and extracellular GSH production. However, when
astrocytes and neuronal cells were cultured together using an insert system and GSH was
measured in each cell population separately, TGF-β1 application still led to a decrease in
GSH levels in astrocytes, but GSH levels in the neurons were slightly higher than control
levels. This finding suggests that TGF-β1 leads to the export of GSH from astrocytes so
that it can be utilized by neurons. This is consistent with the well described function of
astrocytes as a source of substrate for neuronal GSH production (Dringen and Hirrlinger,
2003).
This release of GSH is likely a benefit to neurons. Decreased cellular glutathione
has been shown to occur in schizophrenia (Yao et al., 2006), depression (Godlewska et
al., 2015), and neurodegenerative diseases (Schulz et al., 2000). In these cases it would
be expected that upregulation of system xc- would be beneficial. For example, the
protective effects of TGF-β1 against oxidative stress mediated insults, such as amyloid-β
toxicity (Ren and Flanders, 1996; Shen et al., 2014) could be mediated by the increased
production of GSH. However, with increased system xc- activity the potential for
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increased excitotoxicity also exists. In our mixed cortical cultures excitotoxicity masked
any of TGF-β1’s potentially protective effects against an oxidative insult. 48-hour
application of TGF-β1 alone was not toxic to neurons. However, when cultures were
treated with TGF-β1 for 24 hours and then rotenone was co-applied for 24 hours, which
interferes with mitochondria and increases reactive oxygen species (ROS), TGF-β1
exacerbated the rotenone-induced toxicity. We were able to block this toxicity with the
general AMPA receptor antagonist NBQX, but not the calcium-permeable AMPA
receptor antagonist NASPM or the NMDA receptor antagonist memantine.
These results indicate a specific enhancement of AMPA receptor mediated
excitotoxicity. This finding is consistent with previous studies. TGF-β1 has been shown
to be protective against NMDA receptor mediated excitotoxicity, while it has been shown
to enhance the toxicity of AMPA/kainate receptor mediated excitotoxicity (Prehn and
Miller, 1996). TGF-β1 protection against NMDA receptor mediated toxicity involves
upregulation type 1 plasminogen activator inhibitor (PAI-1) (Buisson et al., 1998;
Docagne et al., 1999). The protection by PAI-1 is due to its inhibition of tPA, which
increases NMDA toxicity by cleaving the NR1 subunit leading to increased NMDA
induced calcium influx (Nicole et al., 2001). The injury promoting effect could be due
to TGF-β1 upregulating AMPA receptor subunits. Interestingly, upregulation of GluA2,
but not the GluA4 subunits has been observed (Bae et al., 2011). Since lack of a GluA2
subunit allows calcium permeability (Hollmann et al., 1991), the upregulation of the
GluA2 subunit is consistent with the results that the toxicity of TGF-β1 treatment in
combination with rotenone is mediated by general AMPA receptors and not calcium
permeable AMPA receptors. Another possibility is that TGF- β1 effects glutamates
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affinity for AMPA receptors. Altering subunit composition or phosphorylation of the
AMPA receptor could change affinity for the receptor and changes in affinity could play
a role in the AMPA receptor mediated death.
The potentiation of toxicity could also be caused by changes in excitatory amino
acid transporter (EAAT) function. EAATs are the mechanism by which glutamate is
removed from the extracellular space and decreased EAAT function can lead to
excitotoxicity (O’Shea, 2002). However, there were no changes in EAAT function, as
measured by radiolabeled D-aspartate uptake (data not shown). This finding is consistent
with other studies that show TGF-β1 does not effect EAAT function (Piani et al., 1993;
Brown, 1999).
In the current study TGF-β1 effects on astrocytes not only led to enhanced rotenone
toxicity in neurons, but it also enhanced rotenone toxicity in astrocytes. The current
study provides interesting differences and similarities to that of He et al. (2015). In that
paper the authors found that treating cultured cortical astrocytes with IL-1β caused an
upregulation of system xc-. They also observed increased release of GSH, but in contrast
to the current study they found an increase in intracellular GSH. What is unusual in the
current study is that TGF-β1 stimulates the release of GSH in astrocytes to such an extent
that GSH levels in astrocytes actually decrease below control levels and can lead to
enhanced rotenone toxicity. This suggests a function of astrocytes in which their purpose
of providing GSH to neurons takes precedence over maintaining their own GSH levels.
The most important implication of the current study is the possibility that some of
the known actions of TGF-β1 are mediated by its regulation of system xc-. In a similar
study, treatment with TGF-β1 was shown to induce death of immature cerebellar neurons
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co-cultured with cerebral astrocytes (Brown, 1999). The mechanism of the toxicity
appeared to be increased release of glutamate from the astrocytes as there was increased
glutamate in the media. Astrocyte conditioned media also was toxic to the neurons and
that toxicity was blocked by an NMDA receptor antagonist. In retrospect, the increased
glutamate release was likely due to upregulation of system xc-. We do not observe
toxicity in our mixed cortical cultures with TGF-β1 treatment without the added insult of
rotenone, possibly due to a high rate of glutamate uptake in our culture system.
TGF-β1 is increased in both the SOD1-G93A mouse model of ALS and in human
ALS patients, and TGF-β1 levels are positively correlated with the duration of the disease
(Houi et al., 2002; Iłzecka et al., 2002; Endo et al., 2015). More specifically,
overproduction of TGF-β1 in astrocytes has been found to accelerate disease progression
in a non-cell autonomous way and inhibiting TGF-β1 signaling can extend survival time
of SOD1-G93A mice (Endo et al., 2015). Interestingly, system xc- is increased in
multiple ALS mouse models, including the SOD1-G93A model (Albano et al., 2013;
Mesci et al., 2015). Similar to inhibiting TGF-β1, deleting xCT in the SOD1 mutant
mouse slows disease progression (Mesci et al., 2015). It is possible that increased TGFβ1 production is responsible for increased system xc- activity in ALS and both may be
potential therapeutic targets.
System xc- is known to be upregulated in gliomas with the consequence of
making the gliomas resistant to oxidative stress (Singer et al., 2015) and the added
problem of increased release of glutamate causing neuronal death surrounding the glioma
leading to increased growth (Ye and Sontheimer, 1999). Because of these actions
inhibitors of system xc- are being proposed as treatment for gliomas (Chung et al., 2005;
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Lo et al., 2008). TGF-β1 is also known to play an important role in promoting glioma
growth and antagonists of TGF-β1 signaling are being tested in clinical trials for the
treatment of gliomas (Joseph et al., 2013; Kaminska et al., 2013). Given our results it is
interesting to speculate that some part of TGF-β1’s stimulation of glioma growth may be
due to its upregulation of system xc-. This undoubtedly would not be the only
mechanism of TGF-β1 action as it has also been shown to promote tumor development
by contributing to angiogenesis (Ueki et al., 1992).
Another possibility is that in certain disease states there is compromised TGF-β1
signaling leading to decreased system xc- function, decreased cellular GSH and therefore
disrupted function. This may be the case in Huntington’s disease. TGF-β1 is decreased
in post-mortem brain tissue from Huntington’s disease patients, in the R6/2 HD mutant
mouse model of Huntington’s disease, and in cultured astrocytes expressing the mutated
form of the huntington gene (Battaglia et al., 2011). Interestingly, xCT levels are also
decreased in the R6/2 HD mouse and cells with the huntington gene mutation have
increased oxidative stress in response to system xc- inhibition (Frederick et al., 2014).
These results raise the possibility that the oxidative stress observed during Huntington’s
disease (Li et al., 2010) may be mediated by decreased system xc- activity as a result of
decreased levels of TGF-β1.
In astrocyte cultures TGF-β1 increases system xc- activity through the
MAPK/ERK pathway. It also decreases GSH levels in astrocytes by increasing GSH
export, even to the detriment of the astrocytes. The exported GSH may be utilized by
neurons; however, TGF-β1 enhances rotenone-induced excitotoxicity in neurons, through
AMPA receptors. Dysregulation of TGF-β1 and system xc- occur in many of the same
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diseased states and it is possible that some of the known actions of TGF-β1 may be
mediated by its regulation of system xc-.
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CHAPTER V
DISCUSSION
General Discussion
The dual actions of system xc- make it of great interest in many neurodegenerative
diseases where oxidative stress and excitotoxicity are involved. The studies described in
this thesis were the first to observe that system xc- is dysregulated in an ALS model and
that intracellular cysteine levels may play an important role in regulating system xcfunction. We also show that TGF-β1 upregulates system xc-, but that this many have
negative consequences on cell death under conditions of high oxidative stress. The
following section discusses some of the major findings of this thesis and the broader
implications of how regulating system xc- affects neuronal death. It also discusses the
limitations of the work done, as well as future studies that are needed in order to further
our understanding of system xc-.
THE REGULATION OF SYSTEM XCThe Age Factor
While studying system xc- function in SOD1-G93A mutant mice, we observed
that its activity decreased with age in non-transgenic littermates (Chapter IV). The role
system xc- plays in development and aging is largely unknown. Glutathione (GSH)
levels are high in neuronal and non-neuronal cells in the immature brain, as well as in
developing neurons of the mature brain (Lowndes et al., 1994; Shih et al., 2006; Sun et
al., 2006). GSH is important for proliferation, differentiation, and viability of neurons
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during development since these are times where metabolic and oxidative demand is high
(Dalton et al., 2004). System xc-’s import of cystine is directly tied to GSH synthesis
(Sagara et al., 1993a); therefore system xc- may play an important role in supplying
developing neurons with the high levels of GSH they need. In support of this idea,
studies show that neuronal death induced by glutamate in immature neurons is a
consequence of increased oxidative damage caused by a depletion of GSH resulting from
system xc- inhibition (Murphy et al., 1990; Shih et al., 2003; Shih et al., 2006).
Astrocytes, fibroblasts, and meningeal cells cultured from both xCT knockout (xCT-/-)
mice and mice with the subtle gray pigmentation mutant phenotype (sut/sut), a xCT loss
of function mutation, are unable to proliferate in vitro and need the reducing agent βmercaptoethanol in order to grow (Sato et al. 2005; Shih et al. 2006). Similarly, our
mixed cortical cultures do not survive if we apply sulfasalazine (SSZ), a system xcinhibitor (Gout et al., 2001), on days in vitro 1-3 (data not shown).
While these data support the hypothesis that system xc- activity is important
during development, western blot analysis suggests that expression of xCT, the functional
subunit of system xc-, is much lower in the developing brain compared to the adult brain
(Shih et al., 2006; La Bella et al., 2007). Also, differing effects of xCT knockout and
xCT mutation on brain morphology have been reported; Shih et al. (2006) report that
sut/sut mice show brain atrophy. However, normal brain appearance has been reported in
xCT-/- and sut/sut mice, suggesting that xCT is not critical for development in vivo (Sato
et al., 2005; Massie et al., 2015). In the adult brain, a study by Liu et al. (2007) used
sut/sut mice to assess cellular proliferation in the subventricular zone and dentate gyrus,
two regions where neuronal development continues into adulthood. The sut/sut mice
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showed a small, non-significant, decrease in cell proliferation of the subventricular zone,
but increased cell proliferation in the dentate gyrus. They concluded that xCT is not
essential to cell proliferation in the adult brain. Overall, it appears that system xc- is
critical for the proliferation and survival of cells in vitro, but lack of system xc- may be
able to be compensated for in vivo.
System xc- might also play a role in aging. The “free radical theory of aging” is
one of the leading theories on the mechanism behind aging. The basic idea is that aging
occurs as a result of irreversible damage caused by an increase in reactive oxygen species
(ROS) (Kregel and Zhang, 2007). ROS increase with age in many organ systems,
including the brain (Driver et al., 2000; Kregel and Zhang, 2007). Along with an
increase in ROS, GSH levels decrease in many different cell types, including
hippocampal neurons, during aging (Lieshout and Peters, 1998; Erden-Inal et al., 2002;
Parihar et al., 2008). In fact, overall GSH levels in the adult brain are significantly lower
compared to the immature brain (Lowndes et al., 1994; Shih et al., 2006). System xcplays a key role in GSH synthesis, therefore it is possible that it plays a role in the aging
process. One hypothesis would be that the decrease in GSH levels seen during aging is
due to a decrease in system xc- activity. In support of this hypothesis we observed a
significant decrease in system xc- activity in the spinal cord slices of SOD1-G93A nontransgenic littermates between the ages of 55 days and 70 days; this lower level of
activity was maintained through 130 days (Albano et al., 2013). Work in system xcknockout mice may also support this hypothesis. 8-10 week old xCT-/- mice have a shift
in their cystine/cysteine redox balance (Sato et al., 2005). They have higher levels of
cystine in their plasma, but no change in cysteine plasma levels. This shift in redox

118
balance is similar to what is seen in elderly patients (Jones et al., 2002), which lead Sato
et al. (2005) to speculate that aging may be accelerated in xCT-/- mice.
While the role of system xc- during development and aging is still unknown, its
role in maintaining balance between ROS and GSH is well known and makes it likely to
be important in both of these life stages. A more detailed study of different age ranges
(embryonic, young pup, adolescent, middle-aged adult, aged) needs to be performed in
order to have a better understanding of how system xc- changes with age.
Cystine/Cysteine Redox Balance
In chapter three of this thesis we provide evidence that suggests cysteine is a more
important regulator of system xc- function than GSH levels. System xc-’s functions of
providing the cell with cystine for GSH synthesis and regulating extracellular glutamate,
often masks its function of regulating the extracellular cystine/cysteine redox state that
surrounds the cellular membrane. Cystine taken up by system xc- is reduced to cysteine.
Cysteine can then be used to synthesize GSH, which can leave the cell and contribute to
the reduced extracellular environment (Wang and Cynader, 2000; Dringen and Hirrlinger,
2003). However, some of the cysteine is also directly exported from the cell via system
ASC, which plays an important role in maintaining the extracellular redox environment
independent of the GSH (Bannai and Ishii, 1982; Jones et al., 2002; Anderson et al.,
2007). Given how important cysteine is to regulating the redox environment of the cell
and how system xc- helps to maintain the cystine/cysteine balance, it is easy to see why
cysteine would be an important regulator of system xc- function.
A study by Banjac et al. (2008) lends support to our conclusions. They found that
expressing xCT in lymphoma cells, which normally take up little cystine, was able to
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protect these cells from oxidative stress. Interestingly however, expressing xCT did not
increase GSH levels, rather it increased both intracellular and extracellular cysteine
levels. They concluded that the protection by xCT was not due to GSH as predicted;
rather it was due to increased cysteine levels. Similarly, glutamate-cysteine ligase (GCL)
knockout cells, which are unable to synthesize GSH and therefore die within 48 hours,
are able to proliferate if xCT is overexpressed due to high intracellular and extracellular
cysteine levels (Mandal et al. 2010).
The mechanism by which cysteine is downregulating system xc- still remains to
be determined. One possibility is that it is inhibiting the transcription factor nuclear
factor erythroid-derived 2 (Nrf-2). Nrf-2 is the main regulator of system xc- and
increases transcription of xCT in response to oxidative stress (Ishii et al., 2000; Sasaki et
al., 2002; Lewerenz et al., 2009). Another possibility is that cysteine inhibits the
phosphorylation of xCT by protein kinase A (PKA). Inhibiting PKA has been shown to
decrease system xc- activity in ex vivo striatal punches (Baker et al. 2002). Future studies
need to be performed in order to determine the mechanism behind cysteine regulation of
system xc-.
Neuronal Regulation
In our culture system we observed that astrocytes co-cultured with neurons that
are killed (mixed cultures treated with 500µM NMDA) have a higher level of 14C-cystine
uptake than astrocytes cultured without neurons (astrocyte-enriched glial cultures). This
observation suggests that when cultured together, neurons release a signal that contributes
to the regulation of system xc- on astrocytes. To determine if this hypothesis was correct
we compared the function of system xc- in astrocyte-enriched glial cultures that were
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treated with media from pure neuronal cultures (PNC) to those treated with media from
other astrocyte-enriched glial cultures. Astrocytes treated with PNC conditioned media
for at least 24 hours had significantly higher 14C-cystine uptake than those treated with
glial media (Figure 5.1A). The system xc- inhibitors SSZ and (S)-4carboxyphenylglycine (CPG) blocked the increase in 14C-cystine uptake showing that it
was through system xc- (Figure 5.1B). To determine what the signal from neurons was
that led to the increase in system xc- function, we tested receptor antagonists against
factors that we know upregulate system xc- on astrocytes in our culture system;
specifically, we tested antagonists against TGF-β1, FGF-2, and PACAP. However, we
were unable to block the increase in 14C-cystine uptake with any of the antagonists tested
(data not shown). While we were unable to determine the exact neuronal signal, we were
able to determine that the neuronal signal mediates the increase in system xc- function
through the MEK/ERK pathway (Figure 5.1C).
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Figure 5.1 A) Astrocyte-enriched
glial cultures treated with PNC
media for 24 or 48 hours had
significantly higher levels of 14Ccystine uptake than those treated
with glial media. B) The system
xc- inhibitors SSZ and CPG
blocked the PNC media mediated
increase in 14C-cystine uptake. C)
The increase in 14C-cystine uptake
mediated by PNC media is
blocked with the MEK/ERK
pathway antagonist, PD98059.
Results are expressed as
mean±s.e.m. (n=8-16) after
normalizing to untreated glial
media uptake. * indicates
significantly different from glial
media; # indicates significant
difference from PNC media, oneway ANOVA (p < 0.05).
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Recently, a study by Kong et al. (2016) found that inhibiting the PACAP receptor
with PACAP6-38 blocked neuron-induced upregulation of system xc-. Although this
finding is in contrast to our observations there are some marked differences between the
two studies. First, they are using cortical cultures from rats, while we use mice. Second,
the culturing methods between the two studies are quite different. Finally, while we also
used the PACAP6-38 antagonist to try to block the neuronal signal, the Kong et al.
(2016) study used a concentration of PACAP6-38 that can block multiple receptors; we
applied a much lower concentration.
Even though we were unable to determine the exact signaling molecule by which
neurons regulate system xc- function on astrocytes, the observation that there is neuronal
regulation is important. As previously discussed, the neuron-astrocyte interaction plays a
large role in synaptic transmission (Araque et al.,1999; Newman, 2003; Bridges et al.,
2012a). For example, the glutamate released from system xc- into the extrasynaptic space
is able to regulate the amount of glutamate released in the synapse, through mGluR2/3
activation (Baker et al., 2002). Glutamate released by system xc- can also regulate
synaptic strength by reducing the number of postsynaptic AMPA receptors (Williams and
Featherstone, 2014). The ability for neurons to modulate the amount of glutamate
released extrasynaptically through system xc- may be a way in which they are able to
control synaptic strength and transmission.
Not only are neuron-astrocyte interactions important for regulating synaptic
transmission, but astrocytes also provide antioxidant support to neurons by
supplying them with GSH precursors (Sagara et al., 1993a; Dringen et al., 1999;
Wang and Cynader, 2000; Shih et al., 2003). The antioxidant support provided by
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astrocytes begins with the transport of cystine into astrocytes through system xc(Kranich et al., 1998). Therefore, it is essential that neurons are able to signal
astrocytes to increase system xc- function when they are in need of increased
antioxidant support. Determining the specific signal released by neurons is of
importance because not only will it provide insight into specific situations when
neuronal regulation of system xc- is necessary, but it may also provide a therapeutic
target by which system xc- function can be up- or downregulated.
TGF-β1
TGF-β1 signaling is dysregulated in response to injury and several
neurodegenerative diseases (Pratt and McPherson, 1997; Flanders et al., 1998; Vivien and
Ali, 2006). While it is mainly thought to be neuroprotective, some evidence suggests that
it might potentiate neuronal injury (Prehn and Miller, 1996; Endo et al., 2015). In
chapter four of this thesis, we presented data showing that TGF-β1 increases system xcfunction on astrocytes. This effect requires the activation of two TGF-βR1 isoforms,
ALK5 and ALK1, which in turn activate the MAPK/ERK pathway. This novel action of
TGF-β1 may provide further insight into its role in neuronal protection/death.
TGF-β1, GSH, and Astrocyte Toxicity
The import of cystine through system xc- activity is directly tied to GSH synthesis
(Sagara et al., 1993a). GSH is able to protect astrocytes from various insults (Kim et al.,
2003; Liddell et al., 2006). However, when we compare the effects of TGF-β1 to the
cytokine interleukin-1β (IL-1β) there are some marked differences in the way that GSH is
regulated and its ability to protect astrocytes. While both TGF-β1 and IL-1β increase
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system xc- function on astrocytes (Fogal et al., 2007; Jackman et al., 2010; Chapter IV),
24-hour application of TGF-β1 decreases intracellular GSH levels in astrocytes, while IL1β increases intracellular GSH levels (He et al., 2015). He et al. also shows that the IL1β-induced increase in GSH production protects astrocytes from ROS-inducing FeSO4
and tert-butyl hydroperoxide (tBOOH) exposure. Not only is TGF-β1 unable to protect
astrocytes from rotenone-induced toxicity, it actually exacerbates its toxicity.
Cytokines are known to have many diverse effects. One possibility for the
marked differences in TGF-β1 and IL-1β’s effects on astrocyte protection could be due to
differential effects on GSH export. While both TGF-β1 and IL-1β increase GSH export
into the extracellular space (He et al., 2015; Chapter IV) they could regulate the GSH
exporter, multidrug resistant protein 1 (MRP-1), differently. IL-1β application does not
change the expression (Ronaldson et al., 2010) or function (He et al., 2015) of MRP-1 in
astrocytes. The effects of TGF-β1 on MRP-1 expression are unknown, however, the
MRP-1 inhibitor MK-571 brings intracellular GSH levels back up to control levels
(Figure 5.2), suggesting TGF-β1 does not affect MRP-1 function. Although MK-571 was
not able to increase GSH levels when co-applied with TGF-β1 to the same level as MK571 under control conditions, we used a fairly low concentration of MK-571 (10µM).
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Figure 5.2 The multidrug resistant protein 1 (MRP-1) inhibitor, MK-571 (10µM),
blocked the decrease in intracellular GSH levels caused by TGF-β1. Results are
expressed as mean±s.e.m. (n=8-16) after normalizing to control. * indicates
significant difference from control, # indicates significant difference from TGFβ1, one-way ANOVA (p < 0.05).
Oxidative stress could be another reason for the differential effects of TGF-β1 and
IL-1β on astrocyte protection. He et al. (2015) has shown that the GSH:GSSG ratio
increases with time in the presence of IL-1β. They use this ratio to show that IL-1β is not
causing an increase in oxidative stress in their astrocytes. An increase in oxidative stress
caused by TGF-β1 application could lead to the decrease in intracellular GSH levels and
account for the increase in rotenone-induced toxicity. TGF-β1’s effects on oxidative
stress are explored in the next section.
TGF-β1 and Oxidative Stress
Studies show that TGF-β1 protects hippocampal neurons against oxidative insult
(Prehn et al., 1994; Henrich-Noack et al., 1996). However, TGF-β1 was found to
increase mitochondrial ROS production in several cell types, leading to increased
oxidative stress (Liu and Desai, 2015). It is also well established that oxidative stress
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can increase system xc- activity (Kim et al., 2001; Dun et al., 2006; Mysona et al., 2009).
In order to determine if the increase in system xc- activity induced by TGF-β1 was
mediated by oxidative stress in astrocyte-enriched glial cultures we applied TGF-β1
(100ng/mL) and measured ROS levels using the DCF assay. Initially we saw an early
increase (at hours 1 and 3) in ROS production after TGF-β1 application (data not shown).
We were able to block the increase in ROS levels at 1 hour with the MAPK/ERK
antagonist, U0126 (data not shown).
These data suggest that TGF-β1 activates the MAPK/ERK pathway, which then
leads to an increase in ROS production. Since the increase in ROS production was seen
after a 1-hour application of TGF-β1 but back down to control levels by 24 hours and the
increase in 14C-cystine uptake through system xc- occurred 24 hours after application of
TGF-β1, we hypothesized that the increase in oxidative stress was mediating the increase
in system xc-. However, we were unable to replicate the increase in ROS production with
1-hour application of TGF-β1 (data not shown). Also, in the 14C-cystine uptake assay we
were unable to block the TGF-β1 mediated increase in system xc- activity with free
radical scavengers. We tested other free radical scavengers, but were still unable to block
the increase in system xc- activity. Therefore, while TGF-β1 inducing an increase in
oxidative stress, which leads to the upregulation of system xc- is an attractive hypothesis,
we were not able to confirm that hypothesis. Limitations of the DCF assay to measure all
types of oxidative stress (Karlsson et al., 2010) and the inability of free radical
scavengers to eliminate all ROS means that the hypothesis may be correct, but we were
unable to confirm it.
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THE EFFECT OF SYSTEM XC- FUNCTION ON NEURONAL DEATH
TGF-β1’s Effects on Neuronal Death
Physiologically TGF-β1’s expression is very low under basal conditions; its
expression and release are upregulated in many neurodegenerative diseases and in
response to CNS injury (Pratt and McPherson, 1997; Flanders et al., 1998; Vivien and
Ali, 2006). Therefore, we were interested in TGF-β1’s effects on neuronal death in
concert with an increase in oxidative stress, a hallmark of many neurodegenerative
diseases. Even though TGF-β1 caused astrocytes to export GSH, which should provide
neuroprotection against the oxidative stress induced by rotenone, TGF-β1 exacerbated
rotenone-induced neuronal death. The AMPA receptor antagonist, NBQX (7.5µM), but
not the NMDA receptor antagonist, memantine (10µM), was able to block the toxicity
caused by the addition of TGF-β1. These results suggest that TGF-β1 exacerbates
rotenone-induced toxicity through an AMPA receptor-mediated excitotoxic mechanism.
In order to determine if the excitotoxicity was caused by an increase in glutamate
release due to TGF-β1’s increase in system xc- activity, blocking system xc- with an
inhibitor would be the next logical experiment. However, since rotenone toxicity is
caused by increased oxidative stress (Li et al., 2003; Sherer et al., 2003) and blocking
system xc- activity with an inhibitor would block GSH production, we found that the
system xc- inhibitor SSZ greatly potentiated normal rotenone toxicity (data not shown).
Therefore, due to the complexity of the experiment, we were unable to directly show that
the increased excitotoxicity seen with TGF-β1 treatment during rotenone exposure was
due to an increase in glutamate released through system xc-. Another way to approach
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answering this question would be to measure extracellular glutamate levels when TGF-β1
is applied, using HPLC. However, in our mixed cultures, which have high glutamate
uptake, we have never been able to measure system xc- mediated glutamate release.
Although we could not obtain direct evidence that the TGF-β1-induced increase
in system xc- activity on astrocytes was responsible for the enhanced rotenone-induced
neuronal death, a study by Brown (1999) lends support to this hypothesis. Brown found
that TGF-β1 causes excitotoxicity in cerebellar neurons only if astrocytes are present. He
concluded that TGF-β1 acted upon astrocytes to cause neuronal death through an increase
in extracellular glutamate. It is possible that the increase in glutamate was due to an
increase in system xc-.
TGF-β1 may also exert its effects through mechanisms other than system xc- that
contribute to the excitotoxicity that Brown (1999) saw in cerebellar neurons and that we
see with rotenone-induced toxicity in cortical neurons. One such possibility is that TGFβ1 causes excitotoxicity by decreasing the astrocytes’ ability to clear glutamate.
However, along with others, we found that TGF-β1 did not affect astrocytes’ ability to
clear extracellular glutamate through excitatory amino acid transporters (EAATs) (Piani
et al., 1993; Brown, 1999).
Another possibility is that TGF-β1 could be affecting AMPA receptor expression
and/or function. TGF-β1 increases GluA2-containing AMPA receptor expression, but
not GluA4-containing AMPA receptors in the hippocampus (Bae et al., 2011), which is
consistent with our rotenone-enhanced excitotoxicity working through general AMPA
receptors, but not Ca2+-permeable AMPA receptors. The question still remains, however,
why is TGF-β1 enhanced excitotoxicity AMPA-mediated and not NMDA-mediated?
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Other studies show a similar mechanism for TGF-β1 mediated toxicity; TGF-β1 protects
against NMDA toxicity but enhances AMPA toxicity (Prehn et al., 1993; Prehn and
Miller, 1996; Buisson et al., 1998). The mechanism of TGF-β1 protection against
NMDA toxicity has been partially determined (Prehn and Krieglstein, 1994; Buisson et
al., 1998), while the mechanism of TGF-β1exacerabtion of AMPA toxicity remains
unclear.
The Effect of Increasing System xc- Function on Neuronal Death
The dual actions of system xc- and its ability to be regulated by a wide range of
compounds and pathologies suggest that it can play an important role in neuronal
protection and death. System xc- takes up cystine from the extracellular space and uses it
in the formation of GSH, which can protect cells from oxidative stress. In fact, immature
primary cortical neurons (Murphy et al., 1990), fetal brain cells (Sagara et al., 1993b),
and neuronal cell lines (Miyamoto et al., 1989; Murphy et al., 1989), rely heavily on
system xc- to protect them from oxidative glutamate toxicity. Oxidative glutamate
toxicity occurs when high levels of extracellular glutamate are applied to cells that lack
glutamate receptors; instead of causing excitotoxicity, high levels of glutamate
competitively inhibit the uptake of cystine through system xc-, causing GSH depletion,
resulting in oxidative stress and cell death (Murphy et al., 1989; Ratan et al., 1994).
Overexpressing xCT or Nrf-2 in astrocytes protects immature neurons from oxidative
glutamate toxicity (Shih et al., 2003; Shih et al., 2006). Ceftriaxone, an antibiotic that
upregulates system xc- activity through the Nrf-2 pathway, has also been shown to protect
against oxidative glutamate toxicity in HT22 cells, which are not sensitive to
excitotoxicity (Lewerenz et al., 2009).
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System xc- can also protect against other types of oxidative stress. Nrf-2
overexpression in vitro protects immature neurons from hydrogen peroxide (H2O2) by
increasing many genes involved in GSH sythesis, including xCT (Shih et al., 2003). The
growth factors insulin-like growth factor (IGF-1) and TGF-β1 increase system xc- activity
on dental pulp cells, which leads to protection from oxidative stress induced by different
dental materials (Pauly et al., 2011). When exposed to diethyl maleate (DEM), which
depletes cellular GSH, glioma cells increase xCT expression and system xc- activity
(Kim et al., 2001). System xc- activity is needed in order to maintain the high levels of
GSH necessary for glioma cells to grow (Chung et al., 2005; Chung and Sontheimer,
2009).
While the above examples show increased system xc- function is protective
against different types of oxidative stress, it is important to point out that immature
neurons, dental pulp cells, and glioma cells, are not sensitive to excitotoxicity. Mature
neurons, however, are susceptible to glutamate-induced excitotoxicity and an increase in
extracellular glutamate released through system xc- can cause excitotoxicity. The growth
factors TGF-β1 and fibroblast growth factor-2 (FGF-2) increase system xc- activity on
astrocytes (Liu et al., 2012; Liu et al. 2014; Chapter IV). TGF-β1 enhances rotenoneinduced neuronal toxicity through AMPA receptors. Similarly, long-term application of
FGF-2 leads to AMPA receptor mediated neuronal death. IL-1β also upregulates system
xc- on astrocytes, which potentiates neuronal death induced by hypoxia and glucose
deprivation (Fogal et al., 2007; Jackman et al., 2010; Jackman et al., 2012). Upregulation
of system xc- on microglia can also cause excitotoxicity in neurons. Microglia activation
by amyloid precursor protein (Barger and Basile, 2001) and aggregated amyloid beta 1-
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40 (Qin et al., 2006) increase glutamate released by system xc-, which leads to neuronal
death. Lipopolysaccharide (LPS) can also activate microglia and cause oligodendrocyte
toxicity through increased system xc- (Domercq et al., 2007).
While these studies suggest that increasing system xc- function has negative
effects on neuronal death, there is no evidence that driving system xc- alone is lethal to
neurons. In fact, under basal conditions our culture media contains 100µM cystine,
which is surely driving system xc- function. Also applying TGF-β1 (Chapter IV), IL-1β
(Fogal et al., 2005) or PACAP (Resch et al. 2014) alone for 24-48 hours, all of which
increase system xc- function, does not lead to neuronal death. In all of the abovementioned studies where upregulation of system xc- led to neuronal death, there was also
another stressor involved: growth factor activation, rotenone, hypoxia, glucose
deprivation, amyloid beta, or LPS. Taken together, the data suggests that while driving
system xc- alone does not cause neuronal death, increased activity on non-neuronal cells,
in concert with a stressor, can lead to neuronal death.
System xc- in Amyotrophic Lateral Sclerosis
One of the most interesting results of this thesis is that system xc- function is
significantly increased in the SOD1-G93A mutant mouse at 70 days of age (Albano et al.,
2013). This was the first study to show that system xc- activity was dysregulated in an
ALS model. However, with system xc-’s ability to regulate both GSH production and
glutamate release the key question remains: does the upregulation of system xc- at 70
days promote neuronal protection or does it contribute to the neuronal death seen in the
SOD1-G93A mutant mouse? As discussed in chapter two of this thesis, elevated levels
of oxidative stress have been seen in the spinal cord of SOD1-G93A mice starting at 60
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days of age (Liu et al., 1998). These data, along with changes in the GSH:GSSG ratio in
the spinal cord of 80 day old SOD1-G93A mice (Chi et al., 2007) suggest that the
elevated system xc- activity we found in 70 day old SOD1-G93A mice is induced by
oxidative stress in order to increase GSH levels to protect against ROS.
In line with this hypothesis that system xc- is upregulated in ALS in order to
provide antioxidant protection, there are a few studies that have assessed the potential
therapeutic effects of N-acetylcysteine (NAC) in models of ALS. NAC is a cysteine prodrug that drives system xc- activity (Kupchik et al., 2012). The results from studies using
NAC to delay symptom onset and increase survival of SOD1-G93A mice have been
mixed. One study that administered NAC orally reported improved rotorod performance,
which is indicative of delayed symptom onset, and increased survival (Andreassen et al.,
2000). However, another study that administered NAC orally in one set of animals and
subcutaneously in another set of animals, did not report delayed symptom onset or
increased survival in either group of animals (Jaarsma et al., 1998). The difference seen
between these two studies may be due to variation in SOD1-G93A copy number. The
first study used SOD1-G93A mice with a fast symptom progression, which is due to a
high number of SOD1-G93A copies. The later study used mice with a lower number of
SOD1-G93A copies, which resulted in a slower progression of the disease.
There is one randomized, double-blind study in human ALS patients being treated
with NAC. Overall, NAC provided a small, non-significant increase in survival, with no
evidence of reduction in disease progression (Louwerse et al., 1995). However, when
divided into subgroups, NAC increased survival of patients with limb onset of the disease
and decreased survival of patients with bulbar onset. Interestingly, riluzole, a drug that
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exerts antiglutamatergic actions and is the only FDA approved drug to treat ALS, also
has different effects on these subgroups. Riluzole increased survival in patients with
bulbar onset but not patients with limb onset (Bensimon et al., 1994; Zoccolella et al.,
2007), suggesting that excitotoxicity plays a larger role in patients with bulbar onset. It is
possible that increased system xc- function may be particularly pronounced in ALS
patients with bulbar onset, in which case driving system xc- with NAC could lead to
excitotoxicity that overwhelms the benefit of increased cystine uptake.
While system xc- may be upregulated in order to provide antioxidant protection,
upregulation also leads to increased glutamate release and could have excitotoxic
consequences. A study using SOD1-G37R mutant mice, which phenotypically have a
much slower progression of the disease than SOD1-G93A mice, observed an increase in
xCT expression in microglia at the onset and symptomatic stages of disease progression
(Mesci et al., 2015). Using SOD1-G37R mice that lack xCT (SOD1-G37R:xCT-/- ) they
found that although symptoms appeared earlier in SOD1-G37R:xCT-/- mice, the disease
progressed more slowly. During the symptomatic stage, SOD1-G37R:xCT-/- mice
maintained grip strength longer and lived longer then SOD1-G37R:xCT+/+ mice; they
also had more surviving motor neurons at the end stage of the disease. Mesci et al.
hypothesize that SOD1-G37R:xCT-/- mice have a slower disease progression due to less
glutamate being released from microglia, since many studies have shown that activated
microglia have increased glutamate release via system xc- (Piani and Fontana, 1994;
Barger and Basile, 2001; Mesci et al., 2015). However, they did not directly measure
glutamate levels in the SOD1-G37R:xCT-/- mice.
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With the dual nature of system xc- it is no surprise that it may play a very complex
role in ALS. System xc- function is upregulated in both SOD1-G93A and SOD1-G37R
mice; however, we found that in SOD1-G93A mice it is upregulated at the
presymptomatic stage, while in the SOD1-G37R mice it is upregulated at the onset and
symptomatic stages (Albano et al., 2013; Mesci et al., 2015). The differences in disease
progression likely have a large impact on when system xc- is upregulated and the effects
this upregulation has in the disease. To this point, as previously described, treating
SOD1 mutant mice and human ALS patients with NAC yielded different results. The
differences seen in all of these studies may be due to differences between the progression
of the disease (in the mutant mice) and onset subgroup (in humans). Further research into
the role system xc- plays during the different stages of disease progression may aid in
understanding the complexity of system xc- in ALS.
Based on the available evidence, one might speculate that in SOD1 mutant mice
system xc- may be initially upregulated in response to increased oxidative stress in order
to provide antioxidant protection, but eventually it may contribute to the excitotoxicity of
motor neurons through increased glutamate release. Inhibiting system xc- at various time
points in ALS disease progression and assessing disease onset, symptoms, and survival
rate would be one way to determine if increasing system xc- is beneficial early on, but
harmful at later stages of the disease. The Food and Drug Administration (FDA) has
approved the system xc- inhibitor SSZ for the treatment of inflammatory bowel disease.
One potential problem with using SSZ is that blocking system xc- may lead to a decrease
in GSH levels, which would mask any of its potentially protective effects. The earlier
symptom onset seen in SOD1-G37R:xCT-/- mice support this idea (Mesci et al., 2015).
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SSZ administration in combination with L-2-oxo-4-thiazolidine carboxylate (OTC) may
circumvent this problem. OTC, also known as Procysteine, is an L-cysteine precursor; it
increases cysteine levels in the brain by being taken up into cells and converted into Lcysteine by the enzyme 5-oxoprolinase (Anderson and Meister, 1989). Since cysteine is
the precursor to GSH, studies have shown that administration of OTC is able to increase
GSH levels both in vitro and in vivo (Kranich et al., 1998; Mesina et al., 1989).
Administering SSZ and OTC at the right time and in the correct dosage has the potential
to block the excitotoxic effects the increase in system xc- might be having, while
supplying the cells with the antioxidant support that blocking system xc- might remove.
The ability of SSZ to reach the brain and spinal cord is another potential concern
when considering its therapeutic potential. Oral administration of SSZ is metabolized by
bacteria found in the gut, into sulfapyridine and 5-aminosalicylic acid, which do not
inhibit system xc- (Azadkhan et al., 1982; Gout et al., 2001). However, intraperitoneal
injection of SSZ has been shown to suppress primary brain tumor growth by inhibiting
system xc- (Gout et al., 2001; Chung et al., 2005) and it has also been shown to dosedependently reduce extracellular glutamate levels in the prefrontal cortex (Lutgen et al.,
2014). Together these studies suggest that SSZ is able to cross the blood brain barrier and
inhibit system xc- when administered intraperitoneally.
Our findings in the SOD1-G93A mouse model of ALS add to a growing literature
that shows dysregulation of system xc- function in many neurodegenerative diseases. In
most neurodegenerative diseases, with the exception of Huntington’s disease, system xcfunction is increased; evidence suggests that this increase may contribute to the neuronal
death seen in many of these diseases. Although in vivo evidence is still needed, the
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damage is likely caused by increased glutamate release into the extrasynaptic space,
which leads to an overactivation of glutamate receptors and cell death. In the EAE model
of multiple sclerosis pharmacological inhibition of system xc- decreased disease severity
(Evonuk et al., 2015); and in one study of the 6-OHDA model of Parkinson’s disease
xCT-/- mice had decreased dopaminergic cell death (Massie et al., 2011). These studies
point to system xc- as a potential therapeutic target by which to slow progression of many
neurodegenerative diseases.
Increasing System xc- and Neuronal Death – A Summary
As previously discussed, there is no evidence that increasing system xc- activity
alone leads to cell death. However, upregulation of system xc- on non-neuronal cells, in a
stressed or neurodegenerative diseased state can lead to neuronal death. Figure 5.3
summarizes the events that may be occurring in a stressed/diseased state, which may
contribute to the neuronal death in these states. In both non-stressed and
stressed/diseased states, upregulation of system xc- leads to increased GSH production
and increased glutamate release. In a non-stressed state we hypothesize that increased
GSH production helps protect neurons from oxidative stress caused by free radicals and
EAATs are able to handle the increased glutamate being released. In a stressed/diseased
state, however, increased glutamate release can lead to excitotoxicity due to ionotrophic
receptor overactivation. The cause of AMPA and NMDA receptor overactivation is
unknown, but may be due to receptor upregulation, recetpor phosphorylation, decreased
EAAT function, or a combination of these events. Decreased EAAT function may also
decrease the uptake of cysteine into neurons, which would decrease GSH production in
neurons leading to increased oxidative stress and contribute to neuronal death.
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Figure 5.3 Hypothetical role of system xc- in contributing to neuronal death
in stressed/diseased states. C-C: cystine; Cys: cysteine; GSH: glutathione; Glu:
glutamate; xc-: system xc-; E: excitatory amino acid transporter; A: AMPA
receptor; N: NMDA receptor; M: metabotropic glutamate receptor; MRP-1:
multidrug resistance protein 1
LIMITATIONS IN STUDYING SYSTEM XCDetecting System xcOne of the biggest challenges of studying system xc- is detecting its expression
and pattern of distribution. Three different xCT transcripts (12, 3.5, and 2.5kb), all easily
induced by a variety of insults, have been detected in macrophages, fibroblasts, and HT22
cells using Northern blot (Sato et al., 1999; Sato et al., 2001; Sato et al., 2002; Sato et al.,
2004; Sato et al., 2005; Lewerenz et al., 2006). The different transcripts are likely a result
of alternative splicing or alternative polyadenylation sites. Northern blot analysis of
different types of tissue also show that the 12kb transcript is found in the brain, but is
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absent from the heart, lungs, liver, and kidneys. The 3.5 and 2.5kb transcripts are absent
from all of the tissue tested, including brain tissue, suggesting that they are mainly found
in cultured macrophages (Sato et al., 1999).
Using RT-qPCR, we measured the change in xCT mRNA levels following TGFβ1 application, using two different sets of primers. Both sets of primers showed that
TGF-β1 increased xCT mRNA levels in a time-dependent manner to a similar extent
(data not shown). Interestingly, our results also showed that the xCT mRNA detected
with the first set of primers was significantly more abundant than that detected with the
second set of primers under control conditions. These results suggest that we are
detecting two different splice variants of xCT.
While using Northern blotting and RT-qPCR are useful, increased xCT mRNA
does not always mean increased functional protein at the membrane. A major hurdle for
studying system xc- is the lack of a specific antibody to detect xCT protein. The amino
acid sequence for xCT is predicted to be 502 amino acids long and have a relative
molecular weight of 55.5kDa (Sato et al., 1999). However, Western blotting with
different antibodies has yielded results with multiple molecular masses. A 50kDa band
was detected in human glioma cells (Kim et al., 2001), while a 45kDa band was detected
in murine fibroblasts (Lewerenz et al., 2009). In Muller cells, both 50kDa and 40kDa
bands were detected (Mysona et al., 2009). The 50kDa band was found both in the
membrane and intracellularly. The 40kDa band, on the other hand, was mainly found
intracellularly; its expression increased in the membrane when the cells were in
conditions of increased oxidative stress. A 40kDa band was also found in human
fibroblasts, and neurons and astrocytes cultured from rats (La Bella et al., 2007). In
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HT22 cells diethyl maleate increased the intensity of a band detected at 40kDa; and this
band was gone following RNAi for xCT (Burdo et al., 2006). Finally, a 35kDa band has
been detected in multiple brain regions in mice and rats (Shih et al., 2006; Massie et al.,
2008; De Bundel et al., 2011; Liefferinge et al., 2016). Some of these studies also show
that the 35kDa band is not present in xCT knockout mice.
A recent study done by Liefferinge et al. (2016) highlights some of the problems
regarding xCT antibodies. Out of 53 antibodies studied, only one was specific enough to
be present in the xCT +/+ mouse and absent in the xCT -/- mouse when used for
immunohistochemistry staining. This was an antibody that was made in-house and it
showed only one band at 35kDa with Western blotting. Using this one specific antibody
they were able to detect xCT expression in the cortex, striatum, hippocampus, midbrain,
thalamus, and amygdala. All of the other antibodies analyzed (including commercially
available antibodies) detected multiple molecular masses with Western blotting and/or
showed non-specific labeling with immunohistochemistry. Liefferinge et al. (2016) also
noted that the bands labeled with Western blot could change between different stocks of
the same antibody. Due to the unreliability of xCT antibodies, in this thesis we focused
on analyzing system xc- function using radiolabeled uptake assays.
Limitations Regarding the Translation of in vitro Studies in vivo
In working with primary cortical cultures we have observed that system xc- is
mainly found on astrocytes. There are a couple of key pieces of evidence that support
this observation. First, 14C-cystine uptake through system xc- is much greater under
control conditions in astrocytes-enriched glial cortical cultures than in either pure
neuronal cultures or pure microglia cultures. Also, when TGF-β1 is applied 14C-cystine
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uptake is only increased in astrocyte-enriched glial cultures. Similarly, other studies have
found that IL-1β and PACAP increase 14C-cystine uptake and xCT mRNA expression in
astrocytes, but not in neuronal or microglial cultures (Jackman et al., 2010; Resch et al.,
2014). Second, we observe similar levels of 14C-cystine uptake in mixed cortical
cultures, which contain both neurons and glial cells, and mixed cortical cultures treated
with 500µM NMDA, which effectively kills the neurons without killing the astrocytes.
Taken together, this data suggests that in our culture system, system xc- is mainly found
and upregulated on astrocytes.
Other in vitro studies show that meninges have a higher rate of radiolabeled
cystine uptake than astrocytes (Shih et al., 2006) and that system xc- is upregulated on
microglia (Piani and Fontana, 1994; Qin et al., 2006; Barger et al., 2007). System xcactivity has even been induced in culture on cells that do not show xCT expression in
vivo (Takada and Bannai, 1984; Watanabe and Bannai, 1987), which raises some
concerns about translating in vitro studies in vivo. Culturing conditions likely make cells
much more reliant on system xc-, which makes its activity much higher in vitro than what
may be found in vivo (Lewerenz et al., 2013). For example, oxygen levels used in
culturing conditions are higher than oxygen levels found in vivo. Cells are normally
cultured under 21% oxygen conditions, which leads to significantly higher levels of
cystine uptake than cells cultured under only 2% oxygen (Bannai et al., 1989; Sato et al.,
2001). Higher levels of oxygen lead to an increase in ROS (Halliwell, 2003) and in order
to be protected, cells must synthesize more GSH. Since cysteine found in the media is
rapidly oxidized to cystine under normal cell culture conditions, in vitro cells rely heavily
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on system xc- to be able to take up cystine from the media to convert it to GSH (Conrad
and Sato, 2012).
Within this thesis there is conflicting data regarding system xc- activity between
work done using in vitro spinal cord glial cells cultured from 1-3 day old SOD1-G93A
mice pups and work done in ex vivo slices from adult SOD1-G93A mice (Chapter II). In
order to further study system xc- in SOD1-G93A mutant mice we cultured spinal cord
glial cells from 1-3 day old pups. Consistently culturing and getting healthy cells to grow
in vitro from SOD1-G93A adult tissue is difficult, therefore it is common to culture cells
from young SOD1-G93A mutant pups (Hensley et al., 2006; Bilsland et al., 2008;
Cassina et al., 2008; Rabinovich-Toidman et al., 2015). After culturing the glial cultures
we insulted them with iron citrate, in order to mimic the increase in oxidative stress seen
in vivo in SOD1-G93A mutant mice. However, when we did this SOD1-G93A nontransgenic littermates had higher levels of cystine uptake than SOD1-G93A mutant mice,
which is the opposite of what we observed in adult spinal cord slices. While in vitro
studies reveal useful insight into the mechanistic and pharmacological characteristics of
system xc-, the differences we see in system xc- activity between in vitro culture and ex
vivo slice, along with the concerns regarding culture conditions, must be kept in mind
when considering what is learned in vitro and translating it in vivo.
Limitations of the DCF assay
The DCF assay is the most commonly used assay to detect oxidative stress
(Kalyanaraman et al., 2012). In this assay the cell-permeable probe, H2DCFDA is added
to the media. Once inside the cell it is de-esterified to form a free acid (H2DCF) that can
then be oxidized to the fluorescent product, DCF, which is easily detected using a
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fluorescent plate reader. Originally thought to mainly detect hydrogen peroxide (H2O2) it
is now known that H2DCF can be oxidized to DCF by the hydroxyl radical (OH-), NO2formed from the nitrite system, hypochlorous acid (HOCl), and reactive species formed
peroxynitrite decomposition (Kalyanaraman et al., 2012).
Although easy to use, in our hands, we found that the DCF assay could give
mixed results. As previously discussed, we used the DCF assay to detect the levels of
oxidative stress inside astrocyte-enriched glial cell cultures following TGF-β1. Initially
we observed an increase in DCF fluorescence following 1-hour TGF-β1 application,
which indicated an increase in intracellular oxidative stress. However, in subsequent
experiments the increase in oxidative stress was no longer detected by the DCF assay.
The mixed results that we observe with the DCF assay may be a result of some of the
assay’s caveats. One such caveat to the assay that may explain our mixed is that H2DCF
is not directly oxidized by H2O2 (Kalyanaraman et al., 2012). A short (30 minute)
exposure of cells to H2O2 only marginally increased DCF in a study by Karlsson et al.
(2010). Therefore, it is possible that if TGF-β1 is increasing system xc- activity by
increasing H2O2 production, the DCF assay may not be able to reliably detect the increase
in H2O2 after only 1-hour.
The DCF assay may also have some more major caveats. The study by Karlsson
et al. (2010) suggests that H2DCF oxidation largely occurs as a result of its interaction
with cytochrome c, a protein released from the mitochondria during apoptosis, and/or its
interaction with iron released from lysosomes, which forms DCF in the presence of
oxygen or H2O2. The study suggests that without the release of cytochrome c and/or iron
only a weak cytosolic fluorescence will be observed, which is likely due to normal
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mitochondrial production of H2O2. These caveats should also be taken into consideration
when interpreting data from the DCF assay.
CONCLUSIONS
The function of system xc- allows it to be influential in determining a cell’s fate.
Its dual nature allows it to protect neurons from oxidative stress but it may also lead to
cell death by releasing too much glutamate into the extracellular space. Although
discovered over 30 years ago, the question still remains: Is upregulation of system xcmore likely to be neuroprotective or lead to cell death? Unfortunately, because of the
complexity of system xc- function and the diseases it is dysregulated in, there is no clear
answer to this question. However, this thesis was able to add to our knowledge about
how system xc- is regulated and its contribution to cell death.
Our study was the first to observe system xc- dysregulation in a model of ALS.
We found that system xc- activity was increased in SOD1-G93A mutant mice at a time
point just after increased oxidative stress was observed. Given its function, this suggests
that system xc- activity is increased in response to oxidative stress in order to provide
antioxidant protection. However, system xc- is increased in many neurodegenerative
diseases and appears to have negative consequences on neuronal death in many of these
diseases. We also found cysteine to be a more important regulator of system xc- activity
than GSH. One of system xc-’s functions is to maintain the cystine/cysteine redox
balance of the cellular membrane; therefore, cysteine’s ability to regulate system xc- is
important, especially since levels of cysteine are more directly related to the uptake of
cystine than levels of GSH. Finally, we showed that TGF-β1 increased system xc-
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activity on astrocytes and that this can have negative consequences on neurons when they
are under increased oxidative stress.
Collectively, there appear to be more studies showing negative consequences of
increased system xc- function on neuronal death and our TGF-β1 study adds to this
collection. However, it is important to point out that most of these observations are seen
in culture and occur when another stressor is involved. Increasing system xc- activity in
vivo may be beneficial in situations where excitotoxicity is limited, but oxidative stress is
occurring. Therapeutically increasing system xc- activity may also be useful in order to
restore impaired glutamatergic signaling, as is seen in diseases like schizophrenia (Baker
et al., 2008; Chen et al., 2010; Lutgen et al., 2014) and addiction (Baker et al., 2003;
Madayag et al., 2007; Kau et al., 2008; Reichel et al., 2011); in which excitotoxicity is
not likely to occur.
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